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1 General Introduction
Classical genetics has been very successful at characterizing genetic disorders such as he-
mophilia, sickle cell anemia and cystic fibrosis. These diseases are caused by a mutation 
in a single gene, and once that gene was discovered, that immediately led to a much bet-
ter understanding of the disorder. But most diseases are more complicated; single-gene 
disorders are the exception rather than the rule. Evolutionary pressure has ensured that 
most cellular processes are robust, and they do not immediately fail when a single gene 
or protein is broken, because alternative pathways can take over. Drugs that are selected 
to target a single protein often turn out to be ineffective because of this redundancy [1]. 
For diseases such as diabetes, asthma and cancer, it has been much harder to gain a better 
understanding and answer important questions. These diseases are caused by a complex 
interplay of genes, environmental factors, diet and lifestyle. To understand them, it is 
not sufficient to look at a small number of genes and proteins. Instead it is necessary 
to study the action of multiple biological pathways as a whole and measure as many of 
the components of those pathways as possible. Many questions in current biological 
research require large amounts of data to be answered [2].
Large amounts of data are needed, and indeed large amounts of data are obtained. 
Technological developments have made it easy to measure a large number of RNA, 
proteins or metabolites at once. Large scale experiments are now so common that a 
whole new terminology has arisen around them. Collections of biomolecules of a cer-
tain type are designated with a word ending with –ome, such as genome for the collec-
tion of all genes, transcriptome for the collection of all (messenger RNA) transcripts, 
and metabolome for the collection of all metabolites. The study of the genome is then 
called genomics, and in similar vein the words transcriptomics, metabolomics and even 
interactomics, phosphoproteomics, lipidomics, localizomics and phenomics have been 
coined [3]. For example, microarrays let you measure the activity of all transcripts and 
can thus be classified as a transcriptomics technology. Equivalent technologies exist for 
the other types of biomolecules. All these technologies are continually improving in ef-
ficiency, sensitivity and specificity.
Each type of data forms a piece of the puzzle. Current biological questions require a full 
overview of all the components of the cell. For example, high glucose levels in the blood 
stimulate the production of insulin by the pancreas. Insulin is carried by the blood to 
other cells, where it activates the insulin receptor pathway. This in turn leads to the ac-
tivation of pathways for the production of amino acids, lipids and glycogen and repres-
sion of gluconeogenesis and ketogenesis. In each pathway, enzymes are phosphorylated, 
gene expression is changed or signaling proteins are shuttled to a different location in 
the cell. In type II diabetes, the ineffective action of insulin can influence all these com-
ponents. Integration of multiple types of omics data will be a cornerstone to achieve 
complete understanding of this disease.
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A pathway can be loosely defined as a set of biological interactions that are function-
ally related. Biological pathways are little more than an abstraction, a simplification to 
make a complicated reality understandable. Pathways can be represented graphically as a 
diagram, displaying a wealth of information about a process in a single view. A pathway 
diagram is suitable as a point of integration of data and knowledge. Pathway diagrams 
may be used to visualize biological knowledge as well as a large number of data points 
at the same time. Software tools are needed to make this possible. Thus, the main goal 
of this thesis is as follows:
Goal: develop methods to integrate multiple types of experimental data and visualize 
them on pathway diagrams.
These methods do not have to be developed from scratch. There are a number of bioin-
formatics projects related to pathway diagrams. Chapter 2 will review the current state 
of pathway representation on computers, including graphical notations, databases and 
file formats.
The main goal can be divided in a few smaller sub goals. 
Sub goal 1: develop user-friendly software to create and view pathway diagrams.
One of the first tools we looked at was GenMAPP [4], which allows pathway creation 
and visualization of datasets, but was limited in several ways: the software was written 
in the inflexible Visual Basic programming language, and only allowed visualization 
of microarray (transcriptomics) data. Chapter 3 describes PathVisio, a new pathway 
visualization tool that was developed as a continuation of GenMAPP, improving upon 
it where possible. 
Sub goal 2: annotate pathway diagrams so they can be linked to experimental data
To be able to link experimental data to pathways, it is important that these pathways 
are annotated correctly, using identifiers from online databases that are standardized and 
globally recognized. PathVisio was developed with this goal in mind.
Sub goal 3: maintain a curated database of pathway diagrams
Data integration on pathways works best when there is a large collection of curated 
pathway diagrams available. Furthermore these diagrams should be continually checked, 
improved and updated when new knowledge becomes available. The GenMAPP group 
has created a large number of pathway diagrams but the small number of active curators 
could not keep up with developments in all biological research. Therefore we developed 
WikiPathways, an online resource for pathway diagrams that can be accessed by anyone, 
facilitating collaborative curation to share the burden of keeping pace with the growing 
body of knowledge. This work is presented in chapter 4.
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Sub goal 4: map identifiers of related biological entities
Just using the right identifiers is not enough. Biological entities are related to each other 
– for example a protein is related to the gene from which it is transcribed, and a microar-
ray probe is related to the gene that it is supposed to measure. If all these biological enti-
ties are described by identifiers, then the question is how these identifiers relate to each 
other. This problem and all its implications are considered in chapter 5. To encourage 
the re-use of code we developed a software framework called BridgeDb that provides a 
generalized solution that is employed by PathVisio, but could also be easily adopted by 
other software projects.
When the results of the work on each sub goal are taken together, we can revisit the 
main goal, which is to develop methods to integrate multiple types of experimental data 
and visualize them on pathway diagrams. In chapter 6 we demonstrate the validity of 
the approach. To make the demonstration realistic we applied our methods to a specific 
research problem. We focused on nutrition research, because it benefits from the multi-
omics approach in particular. We have evolved over millions of years to sustain on a wide 
variety of diets, so our bodies have developed mechanisms to balance dietary changes 
that involve many genes and pathways. Eating something different does not immedi-
ately throw your body out of balance. With this in mind, it is no surprise that nutrition-
related disorders such as obesity and type II diabetes are complex multi-gene diseases.
The biological question that we asked in this case was related to long-term food depriva-
tion. Humans can survive six to eight weeks without food [5], and during that time cells 
in your body respond to make the most of available energy reserves. Each organ in the 
body responds in its own way, and complex interactions take place to make sure that 
vital organs get enough fuel while the non-vital organs are conserving energy as much 
as possible. In the study presented in chapter 6 we look in particular at the role of the 
intestine.
Finally, in chapter 7 conclusions are drawn and the previous chapters are discussed.
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2 Pathways and Pathway Diagrams
14
Figure 1: Glycolysis and Gluconeogenesis pathway in Mus musculus. Source: WikiPathways 
(WP157)[1].
15
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Pathway diagrams are a central concept in this thesis. In this review, some general ques-
tions about pathway diagrams will be answered. See for example Figure 1, which shows 
a diagram of the glycolysis and gluconeogenesis, two well-studied biochemical path-
ways. Upon looking at this diagram, several questions may arise. How was this diagram 
created? What is the meaning of each arrow and each symbol? Is the meaning of these 
symbols formalized?
In glycolysis, glucose is broken down to pyruvate. In gluconeogenesis, glucose is formed 
from smaller molecules. In this case glycolysis and gluconeogenesis are depicted togeth-
er, because they share a large number of steps, but not all sources do that. How do we 
compare pathways and determine where they overlap? How do we determine if compo-
nents on two pathways are the same? How are the endpoints of this pathway defined?
Pathways can be part of textbook knowledge or they can be highly debated as current 
research develops. Discussion is a natural part of science, and we can not always take 
pathway content for granted, as the underlying theories may be reformed at any time. 
Where can we find pathway diagrams to compare with? Where are pathway diagrams 
stored so they can be shared by the scientific community?
what Is a Pathway?
Pathways are many things to many people. A pharmaceutical researcher may look at 
pathways to identify key regulators that could be potential drug targets. A biotechnolo-
gist may think of kinetic modeling of enzymatic reactions in order to predict metabolite 
output of genetically engineered bacteria. A developmental biologist may look at signal-
ing pathways that trigger the differentiation of embryonic stem cells to form blood or 
brain or skin tissues. To satisfy the wide variety of perspectives, the Biological Pathway 
Exchange (BioPAX) community uses the following broad definition: “A set or series 
of interactions, often forming a network, which biologists have found useful to group 
together for organizational, historic, biophysical or other reasons.” [2].
Pathway diagrams are a representation of a scientist’s knowledge in a format that is con-
venient, comprehensive and easy to understand. It formalizes biological entities (genes, 
messengers, proteins, complexes or metabolites) and the relations between them (trans-
port, reaction, conversion). Pathway diagrams can also indicate in which cellular com-
ponents the biological processes take place. Smaller pathways can be merged or large 
pathways can be split depending on the needs of the researcher. The glycolysis pathway 
of Figure 1 could easily be extended on either end with more interactions, such as the 
conversion of other monosaccharides to glucose, or factors that regulate the activity of 
the pathway. 
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For the sake of brevity, the term pathway is sometimes used to refer to both the biologi-
cal entity, and the diagram representing it. For example, the PathVisio program is called 
a “pathway editor”, but it is really the diagrams that are being edited, not the processes 
inside living cells.
Pathway constructIon Process
For every biological research subject, a different pathway can be drawn. Since pathway 
boundaries are not clearly defined, there is no objection to creating a pathway diagram 
that just depicts the processes that are relevant to e.g. a certain disease, or to an inter-
esting mutated genotype. Simply the act of gathering research findings and compiling 
them into a comprehensive pathway is insightful (and it can be recommended to any-
body who is learning about an unfamiliar research area). 
Pathways can be assembled based on various sources. Viswanathan et al. [3] distinguish 
between knowledge driven objective (KDO) and data driven objective (DDO) path-
ways. DDO pathways derive from large experimental datasets (such as co-expression 
data or protein-protein interaction data) and are visualized in the form of large net-
works. KDO pathways are currently mainly derived manually, possibly with the help of 
text mining tools but never primarily by text mining. As a result, KDO pathways have 
a predefined layout. The pathway diagrams considered in this chapter fall almost exclu-
sively in the KDO category.
DDO pathways are often large interaction networks that look like “hair balls”: nodes are 
organized randomly with many crossing edges. This makes them hard to interpret visu-
ally. A good pathway diagram must have a layout that is easy to understand and pleasing 
to the eye. Automatic layout algorithms for pathway models exist and have been used 
successfully. [4-7]. The cellular location of proteins, if known, can provide a useful guide 
for layout algorithms as well [8]. But to compete with manual layouts, layout algorithms 
have to satisfy aesthetic criteria that are sometimes hard to codify, and manual layouts 
are often based on arbitrary conventions. In text book pathways, components may be 
duplicated to minimize edge crossing, a solution that increases computational complex-
ity for layout algorithms. For these reasons, manual layouts can not yet be completely 
substituted by automatic layouts.
Examples of pathways that have been created and curated manually can be found in 
literature [9-14]. Information is gathered primarily from scientific literature, but also 
existing pathway databases and other bioinformatics databases can be used as sources. 
After information is organized and elements are arranged in an understandable layout, 
the pathway diagram should be peer-reviewed by experts. Usually this takes place in 
several iterations. Manual pathway construction is an iterative process, that requires a 
feedback loop between literature research, bioinformatics databases and experts [10].
17
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Automated methods for pathway curation using text-mining can be problematic [3]. 
Natural language processing does not have high enough accuracy to derive pathways 
automatically. When human experts can disagree on the true facts of a pathway, an au-
tomated system can have little hope of achieving better results. Nevertheless text mining 
tools could serve to support manual labor.
Pathway construction can be done using pen and paper, but by using computer software 
the pathway diagram becomes more accessible to editing, sharing, and a variety of other 
uses. This software should provide easy ways to quickly try out various changes to path-
ways, and it should be easy to share and extend pathways with coworkers, either through 
public repositories, or through private communication.
graPhIcal notatIons
Pathway diagrams have been used in textbooks for at least 60 years [15]. However, these 
textbook pathways use ad hoc symbology with hardly any standardization. These ad-hoc 
formats often assign multiple meanings, such as stimulation, catalysis, conversion or 
transport, to the same arrow type. At the same time, different sources may use different 
symbols for the same thing, such as a line ending in a t-bar or an arrow with a minus 
sign to indicate inhibition. This leads to confusion and ambiguity, and hampers the 
interpretation of diagrams. Complex diagrams can not be readily understood without 
extensive explanation in text [15].
It has been pointed out [15, 16] that in other fields of endeavor, a consensus notation 
has been reached. This is the case in object oriented programming (UML), functional 
programming (flow charts) and electronic circuit diagrams. The field of molecular biol-
ogy is lagging in this respect. These other diagram types are in an advantageous position 
because they describe a system (a program, an object model, an electronic circuit) that is 
designed and thus completely known. Biological pathways on the other hand can con-
tain unknown elements that require more research. Nevertheless, a formalized notation 
for pathway diagrams would be useful for communicating biological knowledge, and 
could help forward biological research in areas of high complexity [17]. 
There is a clear trend towards visualization of pathways, even in places where models 
were historically defined purely as a list of reactions. For example Reactome, a database 
centered around biochemical reactions, is now planning to visualize those reactions in 
diagrams [18]. Also the community around the Systems Biology Markup Language 
(SBML), primarily concerned with models intended for computational simulation, has 
created the SBML layout extension to serve the need for visualization of SBML models 
[19] 
1
Pathways are graph-like in nature, but there exist different views on what exactly should 
be represented by the nodes and edges of that graph. Biochemical pathways show how 
metabolites are converted in steps to various end products (for example, pyruvate in the 
case of the glycolysis pathway). In signaling pathways on the other hand, metabolites 
are less important, and gene expression or protein modifications are the primary units 
of activity. The two are not completely separate categories however, as the bottleneck in 
metabolic pathways is often the concentrations of enzymes, which are regulated through 
gene expression. This has an important consequence for correct graphical representation 
of a pathway. In a compound graph, nodes are compounds and edges are reactions (See 
Figure 2). In a reaction graph, nodes are reactions and edges connect consecutive reac-
Figure 2: Four possible graph representations of biochemical pathways. These representations are based on 
Deville et al. [20]
1
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tions. Neither compound graphs nor reaction graphs are capable of expressing both a 
biochemical network and the regulation of that network in the same diagram. A graphi-
cal notation must either be a bipartite graph where nodes and edges can be of different 
classes or a hyper graph where an edge can connect more than 2 nodes [20]. As we will 
see further on, bipartite graph representations are used in current notation standards.
Molecular Interaction Maps
Early efforts for defining a graphical notation [21, 22] were received with interest but 
were not widely adopted. Molecular Interaction Maps (MIM) was the first notation 
that has persisted up to date and was developed with a high level of detail [9, 16, 23, 
24]. PathVisio is currently the only specialized editor for Molecular Interaction Maps 
(Chapter 3).
In molecular interaction maps, different arrowheads are used to represent interactions 
such as conversion, covalent binding, transcription, stimulation and catalysis. The result 
of an interaction is represented by a dot on the interaction line. See Figure 3 for an 
example.
Designers of graphical notations must be able to deal with diagrams that lack sufficient 
detail to allow computational modeling. Often there are too many components of the 
pathway that are simply unknown. MIM recognizes that fact and allows two possible in-
terpretations, namely explicit and heuristic maps. A heuristic map is simply an informa-
tion organizer; explicit maps are intended for computational modeling. The great visual 
complexity of explicit maps does little towards comprehension. If knowledge transfer is 
the goal, then heuristic maps are more practical.
Kitano Process Diagrams
Another notation system that has emerged is Kitano process diagrams [25, 26]. Process 
diagrams are designed primarily to represent biochemical pathways, unlike MIM which 
Figure 3: A small example of MIM notation. Protein 
A can be phosphorylated, which is represented by the ar-
row between P and Protein A. The dot labeled x signifies 
the result of that interaction, i.e. the phosphorylated state 
of Protein A. The double-ended arrow to Protein B repre-
sents complex formation between phosphorylated Protein 
A and Protein B. According to this diagram, phosphoryla-
tion of Protein A is necessary for complex formation. The 
resulting complex is represented by the dot labeled y.
20
is targeted more towards signaling networks. This is reflected by the fact that process 
diagrams have a clear ordering of pathway steps, whereas MIM only show the relations 
between biomolecules but not in what order those biomolecules interact. 
Another issue that must be addressed in graphical notations is the problem of combi-
natorial explosion, which arises when a protein can have a number of possible states. 
States could be covalent modifications, conformational changes or a cellular relocation. 
Each combination of states could lead to different reaction activities or interactions. It is 
not uncommon to have thousands of possible states for a single protein. In process dia-
grams, multiple variants of a protein are represented by multiple glyphs in the diagram, 
which means that they have to be duplicated. This is an important difference with MIM 
notation. In Molecular Interaction Maps, each entity is depicted only once, with a few 
exceptions. An example of this can be seen in Figure 3, in which Protein A is depicted 
only once even though it occurs in two states (phosphorylated and unphosphorylated).
Figure 4: Glycolysis pathway represented using SBGN Process Diagram (PD) notation. In this diagram, 
two types of entity pool nodes can be found. Circles represent small molecular compounds, whereas rounded rect-
angles represent macromolecules (in this case enzymes). Some circles have the lower half colored black. This is a 
clone marker to indicate that these compounds occur multiple times in the diagram. Process nodes that represent 
the reactions are a small square. Arrows pointing to an entity pool node indicate production of that entity, lines 
with a  open circle at the end, pointing to process nodes indicate catalysis.
21
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Systems Biology Graphical Notation (SBGN)
Systems Biology Graphical Notation (SBGN)[15] provides a broad basis for standard-
ization by engaging the scientific community. SBGN draws on the experience with 
MIM and Kitano process diagrams. To serve different uses of pathway diagrams, SBGN 
defines three different languages for specifying pathways at different levels of detail. 
The three sublevels are Activity Flow diagrams (AF), Entity Relationship diagrams (ER) 
and Process Description diagrams (PD). The simplest of the three is the AF diagram, 
which is centered on activities, and which entities participate in those activities. An 
arrow simply means that one activity influences another, but does not have to imply 
physical contact of the biological entities. ER diagrams represent how entities relate 
to each other: which proteins bind to each other, which proteins are phosphorylated 
or otherwise modified. Entity relationship diagrams draw inspiration from Molecular 
Interaction Maps. A PD diagram focuses on processes, i.e. reactions, creation, degrada-
tion, phosphorylation, etc. It is a bipartite graph with one node type called Entity Pool 
Nodes for genes, proteins and metabolites, and a second node type called Process Nodes, 
to represent reactions and other processes. See Figure 4 for an example. The PD language 
of SBGN draws inspiration from, and improves upon, the Kitano process diagrams.
Building on the experience gained in the SBML community, the SBGN developers 
realized that it is impossible to develop a perfect notation system in one sitting. Instead, 
SBGN is released in versions called levels. This is important because it allowed SBGN 
to get an initial version out relatively quickly. The first version is relatively simple, using 
fewer different notation types than MIM.
Experience has shown that certain graphical properties are problematic in day-to-day 
usage. For example color is an issue when photocopying or printing on a black & white 
printer. Line thickness is dubious when scaling the image. For these reasons SBGN 
does not assign meaning to color or line thickness. SBGN also does not prescribe how 
the pathway should be laid out, and there is no biological meaning encoded in layout 
information.
archIval anD exchange of Pathway DIagrams
Many online databases have appeared that collect and distribute pathway diagrams. 
Some of these databases were reviewed before [10, 27]. PathGuide [28] is an extensive 
directory of pathway and interaction databases. At the time of writing, PathGuide lists 
324 resources related to biological pathways, of which 37 are in the category “Pathway 
Diagrams”. From this large number of databases we will highlight only a few, focusing 
on popular choices that include pathway diagrams and demonstrate the range of avail-
able features. 
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When comparing databases of pathway diagrams, we must also consider the file format 
that is used to store them. The file format used determines what the pathways can be 
used for, and which tools can work with them. Standard file formats that are widely used 
are preferable. 
Most pathway databases allow export in various graphics formats. We can distinguish 
vector graphics formats such as SVG and PDF, and raster graphics formats such as PNG 
and JPG. For display on computer screens, the latter is usually sufficient, but for publi-
cation purposes a vector graphics format provides a much sharper resolution.
However, graphics file formats lack the ability to store annotations that are relevant 
to biology. Pathway models should contain biological annotations, in accordance 
with the Minimum Information Requested In the Annotation of biochemical Models 
(MIRIAM) [29]. MIRIAM is an effort to define a standard for annotation of models, 
to enable comparison and exchange. Although MIRIAM is intended for quantitative 
models for use in simulations, most requirements are applicable to any pathway model. 
Besides simple requirements, such as title, author contact details, associated publication, 
time of creation and distribution terms, there is also the requirement that all biological 
entities in the model (genes, proteins, metabolites) are described by a suitable identifier 
linking to a bioinformatics database. Suitable identifiers are unique, perennial and free 
of semantics [30].
Thus we can identify two components of a pathway diagram that can be encoded digi-
tally: a model component, which consists of graph information, annotations and identi-
fiers, and a graphical component, which consists of layout, shapes and the routing of 
connecting lines. The ideal pathway file format must be able to handle both components 
together. Pure graphics formats are not entirely sufficient, neither are formats with only 
biological annotations.
Two relevant existing pathway standards are SBML and BioPAX. These standards are 
openly developed and supported by a broad community. Another notable standard is 
PSI-MI, but it will not be considered here because it is focused on protein interac-
tions and less suitable for pathways in general. All features of PSI-MI are subsumed by 
BioPAX level 2 [31-33]. Besides BioPAX and SBML, many ad hoc pathway exchange 
formats may be encountered in practice, such as KGML (used by KEGG, see below) or 
GPML (used by WikiPathways). These formats did not undergo a standardization pro-
cess because they were developed for a single database, and thus lack broad community 
support.
BioPAX is the most widely recognized and supported standard for pathway data ex-
change. BioPAX is based on the Web Ontology Language (customarily abbreviated as 
OWL instead of WOL). Through OWL, BioPAX defines a data model that is object ori-
ented and set in a hierarchy of classes. Pathways are encoded as a collection of Physical 
23
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Entities and Interactions. For both, there is a tree of subclasses to allow more detailed 
specification. For example, a BiochemicalReaction is a subclass of Conversion, which 
is a subclass of Interaction. Next to Physical Entities and Interactions there is a third 
branch of Utility classes in the hierarchy. BioPAX is used by a wide variety of databases 
and tools, although the broad scope and the difficulties in defining validation criteria in 
OWL make it relatively difficult to work with.
BioPAX does not support storing layout information. For that reason, most pathway 
databases necessarily rely on custom file formats (for example KGML or GPML) that 
contain both annotations and layout data. In order to extract that information, custom 
parses must be used. Thus, the promise of BioPAX to make custom parsers for indi-
vidual database formats obsolete [34] is only partially fulfilled.
Systems Biology Markup language (SBML) can encode quantitative models intended 
for simulation. Pathways encoded in SBML contain species (proteins or metabolites), 
reactions and compartments. Reactions can be described quantitatively using math-
ematical formulas. SBML is advanced in the usage of controlled vocabularies for bio-
logical terms. SBML can store layout data using a special extension [19], although that 
is not yet adopted everywhere.
The main difference between BioPAX and SBML is that the former is aimed mainly at 
the exchange of pathway information between databases, whereas the latter is intended 
as a support for modeling and simulation. Conversion between the two formats without 
loss of data has not yet been demonstrated.
Besides the use of file formats, there are other important points of comparison between 
various databases. Databases differ in the process they use to stay up-to-date. Some 
databases use an extensive curation process with experts, which is relatively slow but 
leads to high quality data. In some cases the group of experts is closed off, making it 
nearly impossible to influence the development of the database. In other cases interested 
experts are invited to join, making the process relatively open. Some databases are open 
to submissions from the general public to correct errors or even add completely new 
diagrams. 
Another point of comparison is the terms of use of pathway diagrams. Commercially 
developed pathway databases are very restrictive, and cannot be improved and redistrib-
uted. Databases developed in the academic environment are usually more open, but the 
terms of use are not always clearly specified. Databases which explicitly state under what 
terms pathways can be used, improved and redistributed, enable scientists to make the 
most optimal use of pathway information.
In Table 1, pathway diagram databases are compared on curation process, supported file 
formats and graphical notations, and license terms.
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Table 1: Overview of the relations between databases, file formats, graphical notations and input tools
Database Input process / 
Curation
Supported File 
Formats
Terms of use Graphical 
Notation
KEGG [35, 36] Developed in house, no 
procedure for external 
contributions.
KGML, BioPAX, 
Raster graphics
Free for aca-
demic use
Ad Hoc
Reactome [18] Curated, Data imported 
using Reactome editor
BioPAX, SBML Free and unre-
stricted
Ad Hoc, 
moving to 
SBGN
WikiPathways 
[37]
Post-hoc curation, Edited 
directly on website by 
any visitor
GPML, 
GenMAPP, Raster 
and Vector graph-
ics
Free (Creative 
Commons 
Attribution 
License)
Ad Hoc
Nature-NCI 
Pathway 
Interaction 
Database [38]
Curated by Editors of 
Nature Publishing Group
XML, BioPAX, 
Raster and Vector 
graphics
Free and unre-
stricted
Ad Hoc
eMIM [39] Developed In House, no 
procedure for external 
contributions. Software 
used: Illustrator and 
PathVisio
Raster and vector 
graphics
Free and unre-
stricted
MIM
BioCyc / 
MetaCyc [40]
External contributions 
are encouraged through 
an adoption system per 
species.
Downloadable 
PGDB format, 
BioPAX, raster 
and vector graph-
ics
Freely available 
to all
Ad Hoc
 
The databases in Table 1 will now be described in more detail.
KEGG Pathway
The database of visual pathways that is probably most popular and most widely used is 
KEGG (Kyoto Encyclopedia for Genes and Genomes) [35, 36]. The KEGG pathway 
collection is only part of a larger database that also contains other biological entities such 
as genes, metabolites and proteins.
KEGG pathways do not use gene or protein identifiers but rather EC numbers for indi-
cating enzymes, which makes them independent of species and tissue. These cross-spe-
cies “reference pathways” can be colored for which reactions actually occur in a species 
of interest.
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There are errors found in KEGG [41], although not necessarily problematic for visual-
ization. The KEGG Pathway set is produced by in house curators; there is no defined 
process for accepting outside contributions.
Besides support for standard BioPAX, KEGG provides its own KGML format which 
includes both biological annotations and layout information.
Reactome
Reactome is organized around biochemical reactions, and multiple reactions are orga-
nized in pathways. Although Reactome is not strictly a database of pathway diagrams, 
some pathways carry a diagram in the description section. More importantly, support 
for diagrams in SBGN graphical notation is currently under development [18] 
Reactome has a well defined process for incorporating new information. Reactome relies 
on a wide network of expert curators, who have to take time to learn to use the Reactome 
Author Tool. Thus getting data into the database is a slow process, but it is in principle 
open to outside contributions. Reactome has grown 2.7 fold in the past three years.
Figure 5: Four online pathway databases. Top-left: Reactome, top-right: eMIM, bottom-left: WikiPathways, 
bottom-right: NCI-Nature Pathway Interaction Database
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Reactome is standards compliant, information can be downloaded in BioPAX and 
SBML formats. The Reactome Author Tool supports drawing in SBGN graphical nota-
tion. Reactome data can be used and redistributed freely.
WikiPathways
WikiPathways is open to contributions not only from experts but any interested party. 
Data in WikiPathways is provided by the public and can also be used freely by the 
public. Data in WikiPathways can be redistributed under the terms of the Creative 
Commons Attribution License.
Currently, a disadvantage of WikiPathways is that it does not support standard pathway 
file formats. Its main file format, GPML, is only supported by few tools (PathVisio, 
WikiPathways, and Eu.Gene). 
WikiPathways supports more than a dozen model organisms. The pathway collection 
for human is the largest. Pathways of other species are partially made through auto-
mated inference from human and partially purpose built.
NCI-Nature Pathway Interaction Database
The NCI-Nature Pathway Interaction Database [38] is created in collaboration between 
the US National Cancer Institute and Nature Publishing Group. Pathway content is 
curated and peer-reviewed. Curation is performed by editors of the Nature Publishing 
Group. The main focus lies on human signaling and regulatory networks.
Pathways are principally derived from research publications, but amended with infor-
mation from Reactome. Additionally, all pathways from BioCarta are incorporated. 
(BioCarta is an older ad-supported database of pathway diagrams, but provides fewer 
features and no standard pathway file formats, so it is a less attractive option).
All data in NCI-Nature PID is freely available without restriction on use. Data is pro-
vided in both a custom XML format and BioPAX Level 2 formats.
eMIM
eMIM forms a small database of pathways, constructed in-house in the Molecular 
Interaction Map notation. The focus is on signaling pathways in humans. It is hard 
to make an exact representation of signalling pathways because of the large number 
of possible states (e.g. phosphorylation states) of many important signaling proteins. 
The eMIM database contains pathways that are a test-bed for detailed representation of 
complex signaling pathways.
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Pathways can be downloaded in various raster and vector graphics formats. Export to 
standard formats is not currently available. The online version of the diagram is linked 
to annotations about the various biomolecules, including literature references. These 
annotations can be found in text or by clicking on the diagram.
The eMIM database is small, but it is the largest collection of diagrams in the MIM 
format. In fact this is the only database consistently using a single graphical notation. A 
database of SBGN diagrams has not yet emerged.
BioCyc/MetaCyc
MetaCyc/BioCyc is one of the oldest comprehensive pathway databases. MetaCyc con-
tains metabolic pathways curated from primary scientific literature. BioCyc contains 
organism specific annotations linked to MetaCyc pathways. Thus, pathways in MetaCyc 
are templates, whereas pathways in BioCyc are filled in with species-specific details.
BioCyc databases are independent but all share the same database schema, which makes 
them interoperable.
MetaCyc/BioCyc has its origin in the annotation of microbial genomes. As a result, the 
bacterium E. coli is the most extensively annotated BioCyc database. In higher species, 
A. thaliana and H. sapiens are the most expansive.
The curation model of MetaCyc is similar to Reactome in its use of a strict but public 
and documented curation process. A species can be adopted by an organization, mean-
ing that they will be responsible for curation of the corresponding BioCyc database. 
Data is available without restrictions. However, unlike Reactome the editor software is 
not freely available and cannot be improved by external contributors. EcoCyc/BioCyc 
supports BioPAX and SBML export, but does not yet support a standard graphical 
notation.
conclusIon
Projects related to pathway diagrams have undergone strong development in recent 
years, which has resulted in the construction of databases, development of graphical 
notations and standardization of exchange formats. It is to be expected that this develop-
ment continues in the near future.
This review should have provided an overview of the current state of these projects. 
Questions to how pathway diagrams are defined, how they are formalized and how they 
can be stored and exchanged should have been answered. One important question was 
not addressed here though: what can we do with a pathway diagram? That question will 
be the focus of the remaining part of this thesis.
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aBstract
Background: Biological pathways are a useful abstraction of biological concepts, and 
software tools to deal with pathway diagrams can help biological research. PathVisio is 
a new visualization tool for biological pathways that mimics the popular GenMAPP 
tool with a completely new Java implementation that allows better integration with 
other open source projects. The GenMAPP MAPP file format is replaced by GPML, a 
new XML file format that provides seamless exchange of graphical pathway information 
among multiple programs.
Results: PathVisio can be combined with other bioinformatics tools to open up three 
possible uses: visual compilation of biological knowledge, interpretation of high-
throughput expression datasets, and computational augmentation of pathways with in-
teraction information. PathVisio is open source software and available at http://www.
pathvisio.org.
Conclusion: PathVisio is a graphical editor for biological pathways, with flexibility and 
ease of use as primary goals. 
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BackgrounD
The concerted actions of genes, proteins, and metabolites are often conceptualized as 
pathway diagrams. Pathways represent a familiar concept in biological research, and 
software designed to work with pathways can help the researcher to organize informa-
tion related to research questions. Here we present PathVisio, a visualization tool for 
managing biological pathways, and show several ways in which this tool can facilitate 
the process of doing research. 
It is often said that an image is worth a thousand words, and this is especially true for de-
scribing complex interactions among biomolecules. Pathways are commonly used with 
great effect as teaching aides in textbooks, as notes in lab journals, and as explanatory 
slides in research presentations. However, a pathway that is drawn in a notebook or pre-
sentation software is just a static image. The usefulness of a pathway could be increased 
dramatically if the software knows something about the biological entities it represents. 
For example, one could click on entities of a pathway to view the Ensembl page of a 
relevant gene in a browser window. Ideally, textbook pathways could be combined or 
compared with other versions of the pathway and stored in an online repository. New 
pathway information could be compiled from the latest experiments and discoveries. 
Large experimental datasets would be more understandable through pathways. Clearly, 
user-friendly software would be helpful for dealing with biological pathways.
Such a tool is currently available and popular with bench biologists: the GenMAPP soft-
ware suite [1] (including MAPPFinder [2] for finding biologically relevant pathways). 
However, GenMAPP has certain limitations in its design that make it difficult to extend 
further. 
A new program, PathVisio, is based on many design principles derived from GenMAPP, 
but uses more flexible programming methods that allow for completely new features 
and increase the possibilities for future extension. PathVisio is designed to augment the 
GenMAPP software suite, replacing some but not all aspects of GenMAPP. PathVisio is 
suitable for the creation and exploration of pathways, while relying on GenMAPP for 
visualization of experimental data and MAPPFinder for statistical analysis. 
PathVisio improves GenMAPP in four separate areas. First, PathVisio is written in the 
Java programming language as opposed to Visual Basic. Thus, PathVisio is easier to in-
tegrate with other scientific software (often written in Java), and it enables integration 
of PathVisio with web technologies such as Java applets and Java Webstart. PathVisio 
already integrates well with some other Java-based scientific tools such as Cytoscape[3] 
for network analysis and Eu.Gene [4] for pathway statistics. Second, PathVisio uses a 
newly designed file format for storing pathway information that is extensible (XML-
 Version 2.0 of PathVisio, released in 2009, does include data visualization features that improve upon 
those found in GenMAPP. See also chapter 6 of this thesis.
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based) yet at the same time backwards compatible with the MAPP format used by 
GenMAPP. This means that the existing GenMAPP pathway archive can be used in 
PathVisio and other GPML-compliant programs. GPML has already been extended 
with new shapes and the capability to define relationships between nodes, allowing a 
network view of the pathway. Because of the novel features of GPML, it is preferable 
to use this format for pathway storage even if the MAPP format is used in later analysis 
steps. Third, the data model is conceptually separated from the rest of the application. 
This enables the implementation of “copy,” “paste,” and “undo” commands, which are 
expected in modern user interfaces, yet are absent in GenMAPP. Abstraction of the data 
model also makes it easier to support different pathway file formats and image formats. 
PathVisio can be used to prepare illustrations suitable for publications with its vector 
graphics export feature. Finally, PathVisio re-implements GenMAPP’s underlying gene 
databases with a new optimized database schema. These four technical improvements 
make the software more flexible, and open the possibility of new functionality and bet-
ter integration with other tools. 
The most important aspect of GenMAPP that has been mimicked in PathVisio is that 
the software places the biologist at the center. We chose to use manual instead of auto-
matic layout, to emulate presentation software that may be already familiar to the user. 
We chose locally installable synonym databases to make cross-referencing gene identi-
fiers quick and automatic. These design choices make PathVisio very user-friendly and 
diminish the need for a specialized intermediate person, who often has less knowledge 
of the biological problem. 
ImPlementatIon
As noted above, the data model of PathVisio is completely separated from the rest of the 
application. It consists of two parts: the pathway data model and the synonym database 
model.
In the pathway data model (Figure 1), there are three main types of objects in a path-
way: DataNode objects represent biological entities, Line objects represent various types 
of interactions, and Shape objects serve as graphical annotation. The term DataNode is 
similar to the GenMAPP term GeneProduct, but we chose to use the former to show 
that it can be used to refer to any type of biological entity, not just genes and proteins. 
DataNodes can be grouped to show that they are biologically related (e.g., for paralo-
gous genes or proteins in a complex).
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Figure 1: Pathway data model. A biological pathway as represented by PathVisio has three main classes of 
objects: DataNodes, Lines and Shapes. The most important are the DataNodes, represented by boxes. These data 
nodes can represent genes, proteins (A), or metabolites (B). DataNodes can be linked to an online database; in 
this example, MDH2 is linked to Entrez gene accession no 4191, and Malate is linked to HMDB identifier 
HDMB03256. DataNodes can be grouped to represent certain biological relationships. In this example, IDH3A, 
IDH3B and IDH3G are grouped to indicate that they form three subunits of a protein complex. A second class 
of objects is formed by lines, t-bars, and arrows that represent interactions between data nodes (C). Various shapes 
and text labels can be used to explain the pathway. In this example, shapes are used to distinguish the cytosol 
from the mitochondrion. (D). The GPML file corresponding to this pathway can be found in the supplemental 
data. The PathVisio source code includes an XML Schema definition that can be used for checking the validity 
of GPML files.
  Additional files are available at the BMC Bioinformatics website at http://www.biomedcentral.
com/1471-2105/9/399
Mitochondrion
Fatty Acid Synthesis
Degradation of Fatty Acids
Containing an Odd Number of Carbons
Degradation of Fatty AcidsGluconeogenesis
Electron Transport Chain
Containing an Even Number of Carbons
Cytosol
Glycolysis
A
B
C D
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To store this pathway model, we developed GPML or GenMAPP Pathway Markup 
Language. GPML is backwards compatible with the GenMAPP MAPP format, mean-
ing that all information stored in MAPP format can be stored in GPML as well, and 
pathways can be readily converted. GPML has a set of extensions on top of the initial 
requirement of compatibility. It allows storing relations among different elements, so 
that a graph can be derived from a pathway. A pathway using this facility can be con-
verted into a network, something that is impossible with the MAPP format. The utility 
of this feature will be discussed below. It also can link to BioPAX [5, 6]. BioPAX is 
an emerging pathway standard for exchange of pathway data. The current version of 
BioPAX (level 2) lacks the ability to store coordinates and graphical annotations that are 
part of the GenMAPP format. By linking GPML elements to BioPAX elements, both 
are extended in XML fashion. In this way, GPML could be used as a presentation layer 
on top of BioPAX. To handle various pathway file formats, PathVisio makes use of a 
generic import /export interface.
The second part of the model used in PathVisio is the synonym database model. A 
variety of online genome databases are available to the bioinformatics community, lead-
ing to multiple identifiers for the same gene. One solution to this problem would have 
been to standardize on a specific database and let users make use of external services 
such as DAVID [7] to translate between ID types. This extra step for the user can be 
cumbersome and prone to errors. PathVisio uses another solution also implemented by 
GenMAPP, letting the software handle the translation through synonym databases.
Synonym databases (called gene databases in GenMAPP) can be downloaded from the 
website pathvisio.org. Because this type of database is potentially used intensively, we 
chose to create locally installable versions rather than relying on a slow web-service. The 
synonym database schema (Figure 2) consists of three tables: “Info”, “DataNode” and 
“Link”. Info provides meta-data on the database. DataNode provides per-gene informa-
tion, including a short description. Link provides a many-to-many relation between 
entries in the DataNode table that is used to store cross-references.
Synonym databases that we produce are based on Ensembl [8] and can in principle be 
made for any species that is annotated in that database. They are produced based on the 
Derby relational database system [9], because Derby can be packaged with the PathVisio 
software making installation easier. However, PathVisio is not tied to a specific database 
back-end. Depending on speed, usability and cost requirements, a different embedded 
or client-server database system could be used through the Java DataBase Connectivity 
(JDBC) layer. The use of synonym databases is not restricted to gene information; me-
tabolites can be used as well to unify PubChem[10], ChEBI[11] and HMDB[12].   
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For viewing pathways, we chose an implementation based on the Java Graphics2D API,            
which makes it possible to output to screen as well as various file types. The flexibility of   
this API makes it trivial to add Shape types in the future. The Batik SVG Toolkit [13] is 
used for exporting to graphic formats, including those suitable for publication. 
results anD DIscussIon
We envision three ways in which PathVisio could aid biologists doing research.
1: Organization of biological information
Many research questions are related to biological pathways in some way. For example, 
which receptor is responsible for carrying a stress signal across the nuclear membrane? 
Which proteins need to be activated to lead to a choice between two possible differenti-
ated cell types? In these cases, a question is asked about a certain unknown component 
of a biological pathway. Experimental results could lead to a conclusion in terms of add-
ing new elements to a pathway, clarifying the role of an element in a pathway, or proving 
Info
version species
1.0 Homo
sapiens
DataNode
id code back-page
ENSG00000146700 En SRCRB4D
ENSG00000146701 En MDH2
ENSG00000146707 En POMZP3
ENSG00000146722 En NR_00360
2.1
4189 L DNAJB9
4190 L MDH1
4191 L MDH2
4192 L MDK
4193 L MDM2
4194 L MDM4
Link
id code id code
ENSG00000146701 En 39001_at X
ENSG00000146701 En 4191 L
ENSG00000146701 En A_14_P108489 Ag
ENSG00000146701 En P40926 S
ENSG00000014641 En ILMN_430 Il
Figure 2: Synonym database schema. This figure represents the database schema for the synonym databases. 
There are three tables, Info, DataNode and Link. Info provides meta-data on the database. DataNode pro-
vides per-gene information, and Link provides a many-to-many relation between entries in the DataNode table 
that is used to store cross-references. The id column contains accession numbers from online biological databases. 
Systemcode is a short code (usually one or two letters) that represents the biological database that the id belongs to. 
A back-page is a short summary of the entity with HTML mark-up, containing at least a one-line description.
3
the existence of an interaction between two elements. In all cases, biological knowledge 
is increased, and since pathways are a representation of this knowledge, the pathway 
itself is improved as a direct result of research. Expressing biological knowledge visually 
as a pathway can be a very powerful tool to organize disparate bits of information. 
What is the best way to represent biological concepts graphically? There are certain 
conventions for this, as well as several published formalized symbolic languages [14-16]. 
The style used by GenMAPP and many textbook pathways does not pose many restric-
tions (e.g., an arrow can be used to mean stimulation, transport to a new compartment 
or simply interaction between proteins). 
Figure 3: Example of a Molecular Interaction Map drawn in PathVisio. The pathway file itself is included 
in the supplemental material.
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Molecular Interaction Maps (MIMs) [16] is one attempt to codify biological knowledge 
in schematics. The advantage of MIMs is that they store a large amount of information 
in a single diagram, and a knowledgeable person can retrieve all this information from 
the diagram with certainty. 
PathVisio 1.0 has some support for MIMs; many of the needed graphical elements can 
be drawn. Work is underway to make this support complete, including making com-
plex aspects of MIMs, such as contingency arrows, available in a user-friendly manner 
(Figure 3). PathVisio is the first graphical editor with support for the MIM style. We 
hope other editors will support MIMs in the future, so that they will be established as 
a standard.
Kitano [17] proposed that a pathway schematic must be semantically and visually un-
ambiguous. The requirement of unambiguously defining a pathway is necessary for 
computational simulation, but is simply impossible for most biological pathways. The 
complexity of these data can be confusing to the biologist or teacher who is attempting 
to convey fundamental aspects of the pathway. For example, the combinatorial explo-
sion that arises when dealing with a protein that can be in different phosphorylation 
states can increase the complexity of the diagram. A trade-off exists between clarity 
and completeness. At the same time, the requirement for unambiguity hampers the 
iterative process by which a pathway can be compiled while research is ongoing. Many 
components of a pathway are unknown and unspecified as long as research has not yet 
provided a full mechanistic explanation of the subject. Kitano resolves this by proposing 
a reduced notation; similarly, Kohn [16] has added a distinction between heuristic and 
explicit maps. GPML allows ambiguity, and doesn’t enforce a particular style of nota-
tion. By being flexible, GPML allows a pathway to progress seamlessly from a rough 
conceptualization to a well established pathway that can be modeled. As increasing lev-
els of complexity are understood, any of the aforementioned styles can be used depend-
ing on the intended use of the pathway.
Biological knowledge stored in a collection of pathways is most useful if it is avail-
able online and frequently updated. An applet version of PathVisio is used for the 
WikiPathways [18] resource, where the research community can collaborate in the task 
of curating and updating pathway content.
2: Data analysis and pathway statistics
Data from high-throughput experiments such as microarrays can be combined with 
pathways to achieve new insights. Using pathways one can view data in its biological 
context rather than in an arbitrarily ordered table. Once a set of pathways have been 
collected in a repository, the possibility to do pathway statistics becomes available.
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PathVisio supports this workflow in combination with the GenMAPP software suite. 
Pathways created with PathVisio can be exported to MAPP format. Subsequently, high-
throughput experimental data can be loaded into GenMAPP, and user-defined color 
criteria established. DataNodes on pathways in GenMAPP can then be colored accord-
ingly, putting relevant parts of the expression dataset together in a single view.
MAPPFinder [2], another tool in the GenMAPP software suite, can be used to search for 
pathways that are significantly regulated under experimental conditions. MAPPFinder 
counts how many genes on each pathway meet user-defined criteria and compares this 
to the expected number of genes that meet the criteria to calculate a z-score. These 
z-scores can then be used to rank a set of pathways, which is very useful in hypothesis-
generating experiments to identify which biological processes are affected.
Eu.Gene can provide an alternative to MAPPFinder in circumstances where something 
other than z-scores is required. PathVisio can export pathways to the Eu.Gene gene list 
format. Eu.Gene can employ Gene Set Enrichment Analysis (GSEA) or Fisher exact 
tests for pathway statistics. 
3: Network analysis and augmentation
Compilation of pathway information is necessarily a manual process, but it would be 
very useful to augment pathway information with computational tools, including text 
mining, data mining and interaction information from high-throughput datasets, such 
as yeast-two-hybrid data.
As an improvement on GenMAPP, GPML has been extended to store node-edge rela-
tions, making it possible to store true interactions. PathVisio allows the user to define 
interactions by joining two items with a connector line. Fore ease of use, the connector 
moves together with the element to which it is connected. 
The user-interface of PathVisio is optimized for the pathway model, meaning that 
PathVisio does not treat pathways as networks. The two concepts are closely related 
however, and network analysis of pathways can be useful. Other software, such as 
Cytoscape [3], is better suited to handle networks. Ideally, one would be able to use both 
programs together. Cytoscape supports a large set of plug-ins [19]. We created a GPML 
plug-in for Cytoscape that enables the user to transfer pathways between PathVisio and 
Cytoscape with copy and paste commands. This is the first step of a workflow for en-
hancing pathway information: 1, Create a pathway in PathVisio based on experimental 
results or literature research. 2, copy the pathway to Cytoscape. 3, Enhance the pathway 
using one of the many sources of interaction information available within Cytoscape. 
For example, the Agilent literature search plug-in could be used to obtain interactions 
from literature. The PathwayCommons plug-in makes various other sources of interac-
tion information available. Once such interaction information is obtained, the network 
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can be further enhanced, for example by grouping nodes by the cellular component 
they occur in using the BubbleRouter plug-in. 4, Copy the enhanced network back to 
PathVisio. 5, Re-arrange the network manually in PathVisio for presentation or publi-
cation. See figure 4 for a schematic overview of this workflow. All plug-ins mentioned 
in this workflow, including the GPML plug-in, can be downloaded directly using the 
Cytoscape plug-in manager.
Future
For a specialized tool such as PathVisio to be relevant, it must be tightly integrated with 
other bioinformatics tools and standards. PathVisio can already be used in combina-
tion with Cytoscape through the GPML plug-in, and it is compatible with GenMAPP 
MAPP format and MAPPFinder for statistical analysis. 
There currently exists a set of partly overlapping pathway format standards [6], and in 
our view, it is better to improve existing standards than to add new ones. As long as no 
Figure 4: Network analysis workflow. This workflow suggests a way to combine manual pathway data and 
results from network analysis. A pathway in GPML format (a) can be copied to the Cytoscape network analysis 
program (b) with copy and paste commands. This program is useful for viewing the pathway as a network (c) 
without any extra graphical annotation. The rich plug-in set of Cytoscape can be used in various ways to extend 
this network. If the extended network contains new information that turns out to be instructive, it may be useful 
to transfer part of this network (d) back to PathVisio again (e) to add manual layout and graphical annotation.
Data analysis
•Omics data
•Functional annotation
•Literature search
•Protein interaction data
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pathway format completely solves all problems, the second best solution is to maximize 
compatibility and interoperability, and a move from a binary format to an XML-based 
format is a step in the right direction. GPML is intended to be a backwards compatible 
extension of the older, less flexible MAPP format. This step makes an older format easier 
to convert and more interoperable with other standards. 
To clarify the role of GPML, we can compare it to other existing standards related to 
pathway definitions. BioPAX is a standard designed for exchanging data between path-
way databases. GPML can embed elements from a BioPAX document and add visual 
annotations to it. This capability could facilitate integration of PathVisio with other 
pathway sources, such as Reactome, in the future. GPML is not suitable for computa-
tional modeling. Systems Biology Markup Language (SBML) is designed specifically 
for that purpose, and the overlap in scope of GPML and SBML is small. SBML defines 
reactions and parameters necessary for computational modeling. GPML instead empha-
sizes links to online databases, as these are valuable for human interpretation.
Besides GenMAPP, a few other non-commercial tools for pathway visualization, such as 
CellDesigner [20] and VisANT [21], already exist. Like Cytoscape, VisANT is oriented 
towards a network view, and since it supports a plug-in interface, a similar GPML trans-
fer mechanism might be implemented in the future. 
PathVisio is fully open source, and GPML is an open format. We see open source as a 
necessity for this type of bioinformatics tool. Open source makes it possible for other 
tools to adapt to PathVisio and vice versa. With closed-source tools (e.g. CellDesigner, 
VisANT and commercial packages), this adaptation can only go one way, which is a 
strong disincentive to collaborate. In a field where integration is of utmost importance, 
open-source software provides an optimal solution. To further encourage cooperative 
development, we will add support for plug-ins, something that is facilitated by the Java 
programming language.
With PathVisio and GPML we have developed a framework for visual pathway analy-
sis. This framework is very flexible with future extensions in mind. Development of 
PathVisio is ongoing. We wish to continue in the direction of increased flexibility and 
tighter integration with other bioinformatics standards and applications. This should 
ensure that pathway analysis and visualization can be done efficiently to improve bio-
logical research.
avaIlaBIlIty & requIrements
Project Name: PathVisio
Project Home Page: http://www.pathvisio.org
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Operating System: tested on Windows XP. Versions for Linux and Mac OS X are under 
development. 
Programming Language: Java
Other Requirements: Java 5 or higher
License: Free and open source under the Apache 2.0 License. There are no restrictions 
to use by non-academics. The source code is available at http://svn.bigcat.unimaas.nl/
pathvisio.
author’s contrIButIons
All authors have read and agreed upon the content of this article. The PathVisio software 
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ing. AP and BC created the GPML concept, CE the PathVisio concept. MvI and SC 
drafted the paper.
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The exponential growth of diverse types of biological data presents the research com-
munity with an unprecedented challenge and opportunity. The challenge is to stay afloat 
in the flood of biological data, keeping it as accessible, up-to-date, and integrated as 
possible. The opportunity is to cultivate new models of data curation and exchange that 
take advantage of direct participation by a greater portion of the community.
This combination of challenge and opportunity is especially relevant to the task of col-
lecting biological pathway information. Pathways are critical to understanding the func-
tions of individual genes and proteins in terms of systems and processes that contribute 
to normal physiology and to disease. Each biological pathway must be hewn from a 
mass of biological information distributed across multiple publications and databases.
The particular challenge of pathway curation is amplified because pathways are often 
presented as static images that are not amenable to computation, integration, or data ex-
change. Furthermore, pathway experts are distributed throughout the world, and most 
have limited time to learn about complex databases that need their expertise. This chal-
lenge can be met by taking the opportunity to develop a new community-based model 
for pathway curation.
One way to engage the community is with a wiki model as exemplified by Wikipedia 
[1]. We see the potential for a wiki-based pathway curation resource, coupled with an 
embedded graphical pathway editing tool, to meet the growing challenge presented by 
the influx of biological data and to provide an innovative example of content curation 
by the biology community (Figure 1).
facIng the challenge
The research community is experiencing massive growth in biological data, from ge-
nome and metagenome sequencing to high-throughput assays and microarray studies. 
This growth has created a need for models of data storage and distribution that support 
a continuous stream of end-user submissions, frequent updates, integrated search across 
databases, and access to data formats (preferably community standards) that are ame-
nable to computational analyses. By and large, the need is being met for certain types 
of biological data: sequences go to GenBank and EMBL-Bank, protein structures go to 
the Protein Data Bank (PDB), and microarray results go to Gene Expression Omnibus 
(GEO) and ArrayExpress. But as the influx and complexity of biological data continues 
to grow, so will the challenge of organizing and maintaining these databases. 
Fortunately, the biology community can provide an answer that will scale with the chal-
lenge: community curation. There is a growing tendency toward information exchange 
that supports open access, higher-order organization, community-defined data formats 
and collaborative online environments. This trend is most apparent with the growing 
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Plenumber of open access journals [2], public databases [3], and data exchange formats [4] and ontologies [5]. To promote community curation, database maintainers must be 
willing to relinquish some control. After removing logistical as well as technical barriers 
with creative support tools, the data producer will also be the data organizer. Despite 
initial misgivings, such projects do succeed with the right balance of infrastructure, 
participation and administrative principles, as demonstrated by Wikipedia [1], numer-
ous open source software projects (e.g., Linux, Apache, MySQL, Firefox), and countless 
scientific collaborations, including the Internet, itself.  The idea of using wiki technol-
ogy for biological information has been proposed in other areas, for example, genome 
annotation [6,7]. The EcoliWiki provides a working example of community curation 
focused on E.coli [8]. And WikiProteins aims to combine automated text mining with 
community curation to annotate biomedical concepts, including protein functions, in-
teractions and disease relationships [9].
Figure 1. Two models for managing biological data. Current biological databases provide the community 
with data submission forms or tools and access to the compiled data via websites, FTP sites and, sometimes, pro-
grammatic interfaces (API). Internal curation teams organize and update the data. A wiki model for biological 
databases, such as WikiPathways, provides a single, intuitive interface for submitting, updating, organizing, and 
accessing data, allowing the community to participate in the curation process and keep up with the influx of new 
data. The widths of the arrows represent the relative capacity for data management in the two models.
4
rePresentIng BIologIcal Pathways
Biological pathways present a special case in which the information is not directly cou-
pled to data collection. One does not sequence or measure a pathway. Pathways com-
prise a myriad of interactions, reactions, and regulations, often identified piecemeal 
over extended periods and by a variety of researchers. As a result, pathway information 
is particularly challenging to compile and curate. Furthermore, biological pathways 
are often captured only as static images for publications or presentations. Consider the 
pathway illustrations common in textbooks and review articles that document any given 
field of biology. A typical signaling pathway, for example, represents receptor-binding 
events, protein complexes, phosphorylation reactions, translocations, and transcription-
al regulation, with only a minimal set of symbols, lines and arrows. While these simple 
images are powerful visual and conceptual representations, they cannot be connected to 
relevant biological annotations or analyzed with respect to experimental data. 
A number of groups have taken on the challenge of curating and archiving biological 
pathways [10]. Those efforts mainly rely on internally supported teams of biologists 
or contracts with volunteer experts in particular fields of biology. Their curation tools 
typically require download, installation, and specialized training and are not designed 
for broad or collaborative use. Often, the barrier is simply too high for the average 
biologist to consider contributing their own pathway knowledge. Even when it is con-
tributed, pathway information can remain untouched for years in the current databases, 
quickly becoming outdated and out-of-sync with the continuing stream of published 
discoveries. Some of us (BRC, KH, ARP) have first-hand experience with maintaining 
the GenMAPP [11] pathway archive in this fashion over the past 8 years. The task of 
submitting and updating content inevitably falls on a handful of specialists who have 
invested significant time installing and learning how to use the curation tools. This ap-
proach is not sustainable in the face of the growing influx of biological data. Clearly, 
curating all of biology is a Herculean task for any single group.
Pathway eDItIng for the PeoPle
To facilitate the contribution and maintenance of pathway information by the biol-
ogy community, we established WikiPathways (www.wikipathways.org). WikiPathways 
is an open, collaborative platform dedicated to the curation of biological pathways. 
WikiPathways thus presents a new model for pathway databases that enhances and 
complements ongoing efforts [12-14]. Building on the same MediaWiki open source 
software that powers Wikipedia, we added a custom graphical pathway editing tool 
and integrated databases covering major gene, protein, and small-molecule systems. The 
familiar web-based format of WikiPathways greatly reduces the barrier to participate in 
pathway curation. More importantly, the open, public approach of WikiPathways al-
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lows for broader participation by the entire community, ranging from students to senior 
experts in each field.  This approach also shifts the bulk of peer review, editorial curation, 
and maintenance to the community. 
Each pathway at WikiPathways has a dedicated wiki page, displaying the current dia-
gram, description, references, version history, and component gene, protein and me-
tabolite lists (Figure 2). Any pathway can be edited from within its wiki page by activat-
ing an embedded pathway editor. WikiPathways uses an applet version of PathVisio—a 
pathway-drawing tool we developed for pathway curation [15] (manuscript submit-
ted). PathVisio provides a basic palette of objects and annotations needed to represent 
biological processes. Gene, protein, and metabolite objects directly map to biological 
annotations from multiple public databases through an extensible identifier synonym 
database maintained at WikiPathways. The editing tool facilitates annotation with key-
word search and auto-completion. Relationships between entities can easily be drawn 
Figure 2. Sample WikiPathways page. Each pathway has a dedicated page for viewing and editing con-
tent. The pathway diagram is edited with an embedded applet version of PathVisio (inset). Description and 
Bibliography sections can be edited in-page as well through applets that facilitate entry. Additional information 
about the pathway components and version history continue on the page (not shown).
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using “smart connectors” that snap into place. Lines can even connect to other lines 
to intuitively represent catalysis or other mediated processes. Entities can be grouped 
to represent complexes and related collections of genes. The editing tool also makes 
it easy to annotate these entities and relationships with peer-reviewed literature refer-
ences. The ‘Help’ section of WikiPathways provides guidelines and tutorials for how 
to use the editor and best represent pathway information, as well as how to download 
and use the pathways in GenMAPP analyses. 
After editing, an updated pathway image is displayed on the wiki page along with the 
version history and list of components. Users can easily monitor and undo changes, 
compare differences and search for overlapping pathways. Any registered user can add 
a pathway to their “watch list” so that they receive email when the pathway is changed. 
All changes can be reversed, restoring the pathway to an earlier version. Different ver-
sions of pathways can be compared side-by-side using an integrated difference-viewing 
tool, customized for graphical pathway information. Using the search feature, one can 
locate particular pathways by name, by the genes and proteins they contain, or by the 
text displayed in their descriptions and comments. One can also browse the collection of 
pathways with combinations of species names and ontology-based categories. Currently, 
WikiPathways contains 537 species-specific pathways for human, mouse, rat, zebrafish, 
fruit fly, worm, and yeast. The mouse pathways, for example, contain 3741 unique genes 
(~13% of the mouse genome). The pathway collection was nucleated with GenMAPP 
pathways, which were collected over the past decade from GenMAPP users. Now at 
WikiPathways, the collection is growing and improving through new contributions and 
curation, at an unprecedented rate, which we expect to dramatically increase as com-
munity participation grows.
The pathway content at WikiPathways is freely available for download in a variety of 
data and image formats, including GPML, which is a custom XML format compat-
ible with pathway visualization and analysis tools such as Cytoscape [16], GenMAPP 
[11] and PathVisio [14]. GPML allows researchers to draw and identify the molecular 
participants in a pathway, as well as the relationships among the participants. GPML 
is a work in progress and though it does not yet have the full expressiveness of BioPAX 
[17] or SBML [18], it provides the basic functionality for researchers to create appealing 
pathway diagrams and to perform basic statistical tests on pathways such as overrep-
resentation analysis. The goal of GPML is to bridge the simple elegance of a pathway 
drawn on a napkin by a biologist (including its rich, human interpretability) and the 
growing databases of gene and protein annotations, interactions and experimental data. 
We prioritized the development of GPML based on what is already available and what 
is most useful to the average biologist: connecting intuitive, human-readable graphics to 
standardized identifiers from popular databases. This allows users to accurately label en-
tities on pathways and computationally map them to experimental data using pathway 
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analysis software. GPML also supports the representation of relationships between enti-
ties to allow network-based visualization and analysis. In a recent “community curation 
event” at WikiPathways we formalized network relationships in the human pathway 
archive. We plan to include a number of BioPAX elements into GPML to support data 
exchange, but the overriding goal for GPML is to lower the barrier for contributors 
of pathway information by keeping it simple. This approach resonates with the large 
portion of the biology community interested in basic statistical pathway analyses and 
figures for publications and presentations. 
To assist pathway authors and curators, we are developing ‘bots’ to survey the content 
and identify potential inconsistencies, redundancies and incomplete data. The first of 
these bots identifies all the genes, proteins and metabolites in any pathway that are 
not connected to a synonym database identifier. These reports along with additional 
curator tools will help contributors to submit high-quality content and make correc-
tions where needed. We also plan to use standard biomedical ontologies to structure 
the content of WikiPathways and to provide organization that can scale with rapidly 
growing and interrelated information.
Researchers interested in particular interactions or pathways can use WikiPathways as a 
resource for up-to-date pathway information and as a repository for their own findings 
that, in turn, are immediately available in multiple data formats for analysis as well as 
image formats for publication. WikiPathways can be used collaboratively to create, edit, 
and share pathway information with any colleague who has access to a web browser. For 
sensitive content that is proprietary or must first be published as an original finding, 
pathways can be saved locally in the GPML format, ready to be uploaded and made 
public at a later time. Expert curators can use WikiPathways to monitor and update 
pathway information associated with their fields of interest. WikiPathways is also use-
ful to students and professors of biology, providing pathways as educational materials 
and the editing history of a given pathway as an example of how scientific knowledge 
iteratively progresses.
To encourage participation by the community we have built templates for ‘User pages’ 
and ‘Portals’. User pages help users identify themselves and their work, while Portals help 
entire communities of users to identify themselves collectively and focus on particular 
pathway domains, such as diabetes-related pathways or plant pathways. By using the 
template you can build a site within WikiPathways dedicated to your lab, organization 
or area of interest within minutes.  We are also organizing community curation events 
as a way to introduce new users to the curation tools and, at the same time, improve the 
quality of the pathway content. Future community curation events will focus on adding 
annotation, group representations, and literature references. 
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Even prior to this publication introducing WikiPathways, we have seen strong signs of 
community participation. Outside of the immediate group of developers, WikiPathways 
has already attracted 10 new mouse pathways, 9 new human pathways, 6 new zebrafish 
pathways, 3 new rat pathways and a Portal for the micro-nutrients community. There 
are dozens of E. coli and plant pathways currently being converted, and 3 new Portals 
under construction. The site has over 220 registered users (10% contributing users) and 
has attracted developers through the Google Summer of Code program.
We envision WikiPathways being part of a broader effort to extend curation capacity 
to larger groups and communities.  This effort does not replace current approaches 
involving centralized teams of curators, but rather it complements and extends them. 
Eventually, we would like to see wiki solutions like WikiPathways utilized by current 
databases and curation sources.  Our future directions include supporting “reference” 
pathways contributed by other pathway databases, and private workspaces for groups to 
collaboratively work on pathways before making them public. You could also imagine 
organizations installing local instances of WikiPathways for internal projects at research 
institutes or biotechnology companies. A journal, for example, could host a version of 
WikiPathways that only contributing authors can edit. Where the same wiki technol-
ogy is used, there are opportunities for seamless integration and controlled sharing of 
content when it is ready to be published or released to the public site. We will continue 
to work towards supporting broad implementations of WikiPathways to promote con-
tributions from established and diverse sources.
WikiPathways is an experiment. We have considerable work ahead in developing the 
GPML data model, implementing critical features and, most importantly, building a 
community of users and contributors. The success of WikiPathways will depend on the 
overall quality of its content, which will be a function of the infrastructure and admin-
istrative principles we employ in addition to community participation. Features such 
as database connectivity, automatic consistency checks, curation tools, reversible edits, 
the visual difference viewer, and support by literature references will assist in tracking 
and reverting errant contributions, stimulating curation by the community. We antici-
pate that lowering the entry barrier for participation will allow for a greater capacity of 
curation, broader consensus on content, and ultimately, higher quality control. We are 
confident that WikiPathways will be a powerful resource for the research community 
and a vital forum for pathway curation. And we are hopeful that it will serve as an 
example for how the continuing flood of biological data can be managed and utilized 
by the community to irrigate future hypotheses and discoveries.
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We are committed to open access and open source. All content is available under a 
Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0/). All 
source code for WikiPathways and the PathVisio applet is available under the Apache 
License, Version 2.0 (http://www.apache.org/licenses/).  You can download the code 
from:
•	 http://svn.bigcat.unimaas.nl/wikipathways
•	 http://svn.bigcat.unimaas.nl/pathvisio
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aBstract
Background: Many complementary solutions are available for the identifier mapping 
problem. This creates an opportunity for bioinformatics tool developers. Tools can be 
made to flexibly support multiple mapping services or mapping services could be com-
bined to get broader coverage. This approach requires an interface layer between tools 
and mapping services. 
Results: Here we present BridgeDb, a software framework for gene, protein and me-
tabolite identifier mapping. This framework provides a standardized interface layer 
through which bioinformatics tools can be connected to different identifier mapping 
services. This approach makes it easier for tool developers to support identifier mapping. 
Mapping services can be combined or merged to support multi-omics experiments or to 
integrate custom microarray annotations. BridgeDb provides its own ready-to-go map-
ping services, both in webservice and local database forms. However, the framework is 
intended for customization and adaptation to any identifier mapping service. BridgeDb 
has already been integrated into several bioinformatics applications. 
Conclusion: By uncoupling bioinformatics tools from mapping services, BridgeDb im-
proves capability and flexibility of those tools. All described software is open source and 
available at http://www.bridgedb.org.
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BackgrounD
Many interesting problems in bioinformatics require the integration of experimental 
data from different sources. Examples include merging two independently created pro-
tein-protein interaction networks in Cytoscape [1] and visualizing microarray data on 
a collection of biological pathways in GenMAPP [2] or PathVisio [3]. More often than 
not, data of different types and from different sources are annotated with different iden-
tifiers. Thus, an important step in the analysis workflow is deducing which identifiers 
from one set correspond to which identifiers in the other set. 
This problem of identifier mapping has been recognized, and a number of resources 
have been developed to solve it, including DICT [4], CRONOS [5], MatchMiner [6], 
AliasServer [7], PICR [8], Synergizer [9] and Ensembl BioMart [10]. For the most part, 
these resources accurately map identifiers and provide an interface, usually a web site, to 
the mappings. However, each resource necessarily has a focused domain of application 
based on limitations in resources and in the interest of its developers. Mapping services 
differ in aspects, such as coverage of species, coverage of identifier types, access speed 
and frequency of database updates. This has created two challenges for developers of 
bioinformatics applications. The first challenge is to develop software that is not tied to a 
single identifier mapping service. Tools that are built around a single service would have 
to be adapted with considerable effort if a more suitable service comes along. Optimally, 
switching should be a simple matter of configuration. The second challenge is to com-
bine mapping services to get the benefits of each. For example, one could combine a 
small mapping table of probe identifiers of a custom microarray with a large mapping 
resource, such as Ensembl BioMart, or one could combine metabolite mappings and 
gene mappings when assessing experimental data from a combination of different omics 
platforms.
The key to both challenges is to create a standard interface between tools and mapping 
services. Here we present BridgeDb, a framework that provides such a standard inter-
face. BridgeDb is a software library intended to be used by bioinformatics tool develop-
ers. The overall architecture is described in Figure 1. BridgeDb makes is possible to write 
shorter and simpler code to handle identifier mapping. This framework has already been 
incorporated in several bioinformatics applications.
Concepts
To explain the features of the BridgeDb framework, it is necessary to define some con-
cepts. We use the term data source to describe a database of biological entities, indexed 
by unique identifiers. Usually, these identifiers are assigned and maintained internally 
by an independent organization. Examples of data sources include Ensembl, UniProt, 
ChEBI, and the Gene Ontology.
5
An internal identifier is an identifier that is valid within the namespace of a data source. 
A good identifier must be unique, stable, and preferably free of semantic information. 
An internal identifier is not necessarily globally unique because a given identifier may 
be valid for two different data sources (this is especially the case for data sources that use 
simple integers as identifiers, such as Entrez Gene and PubChem).
In contrast with identifiers, we use the term symbol for a string that is a human readable 
representation of a biological entity. Symbols are not necessarily guaranteed to be unique 
or stable over time. A symbol can be a gene name such as INSR or TP53 for example. A 
biological entity might have several synonymous symbols or aliases. Since these symbols 
have a biological meaning, they are not semantic-free and do not serve as good identi-
fiers. Semantics should be avoided because the information can be found to be “wrong” 
by new evidence. For example, the Caenorhabditis elegans gene symbol rad-5 (implying 
radiation sensitivity) was replaced by clk-2 (implying a function in developmental tim-
ing) after additional experimental evidence was collected and reinterpreted [11]. 
A global identifier is a globally unique identifier based on the combination of data 
source and internal identifier. Importantly, for the exchange of data, global identifiers 
must be standardized. For the representation of global identifiers, BridgeDb relies on 
the MIRIAM URI standard [12]. MIRIAM describes a minimal set of information to 
define a biological model and requires that biological identifiers be sufficiently descrip-
tive. A valid MIRIAM URI contains both the data source and internal identifier (e.g., 
urn:miriam:uniprot:P62158).
Figure 1: The BridgeDb architecture. BridgeDb provides a channel to connect multiple bioinformatics tools, 
such as Cytoscape or PathVisio, with online and offline identifier mapping services. 
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We use the term mapping service to describe a resource for mapping information 
among identifiers from two or more data sources. This broad definition could include 
simple tables in a text file as well as complete relational databases or online web services 
such as Ensembl BioMart and PICR.
Transitivity
BridgeDb allows stacking, or combining, of different mapping sources both in transitive 
and non-transitive modes. Transitivity means the inference of second- or even third-de-
gree mappings from direct mappings. Transitivity becomes an important issue especially 
when combining mapping services in a stack. In general it is preferable to make use of 
global resources such as Ensembl BioMart for annotation of microarray data, but this 
is not possible for custom microarrays that are not distributed widely. In those cases, 
custom annotation files must be used. A custom annotation file can be produced to map 
custom identifiers to all other biological identifiers that one might wish to consider. But 
BridgeDb allows an alternative approach, where one only needs a very simple mapping 
of custom identifiers to one gene identifier, and can rely on Ensembl BioMart to provide 
the rest. For example, if the custom annotation file defines relations between custom 
identifiers and Entrez Gene, and Ensembl BioMart provides mapping between Ensembl 
and Entrez Gene, then mappings between the custom identifier and Ensembl can be in-
ferred. In this way, the task of creating custom annotations is much simpler, while at the 
same time enabling broader coverage of data sources. This process is depicted in Figure 
2. In the same way two specialized mapping services could be chained together. For 
example, PICR is specialized in proteins and is not normally capable of mapping gene 
identifiers. However, PICR can be combined with Ensembl BioMart, using the latter 
to translate gene identifiers into protein identifiers that the former can understand. In 
principle, transitive mapping from genes to transcripts to proteins could be achieved.
ImPlementatIon
The implementation of BridgeDb is described here for each of the three layers of Figure 
1: tools, interface and mapping services, starting with the interface. 
Implementation of the interface layer
The Application Programming Interface (API) of BridgeDb takes two different forms. 
The first form is based on Java and is suitable for Java applications. The other is based 
on Representational State Transfer (REST) and is suitable for all other programming 
languages.
BridgeDb Java API The structure of the Java API is represented in Figure 3. The central 
BridgeDb class keeps track of all available IDMapper implementations and provides 
uniform access to them through the static connect method. This method takes a con-
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nection string, which contains the requested mapping service and all parameters for 
configuring that service. To access a completely different mapping service, only the con-
nection string has to be modified, the rest of the program can stay the same. The connect 
method returns an implementation of the IDMapper interface. This interface provides 
methods for mapping identifiers, as well as free text search and capability introspec-
tion. The mapID method of IDMapper performs the actual mapping job. It takes an 
Xref object as argument. Xref is a combination of a data source and a local identifier; 
these two are combined to form a global identifier. The Xref class also provides methods 
for generating valid web links to pages describing a biological entity, and for gener-
ating a valid MIRIAM URI. Data sources are themselves represented by DataSource 
objects, which also hold extra information such as web links to the main page of a data 
source. We have created a simple example in Java that shows how to map identifiers 
Figure 2: Transitive relationships between identifiers. In this diagram, two mapping sources (named A and 
B) are combined. Mapping source A defines relations between Ensembl and Entrez genes. Mapping source B is a 
custom microarray annotation that provides mappings between custom identifiers and Entrez. Through transitiv-
ity, the relation between the custom microarray and Ensembl can be inferred. The custom annotation file needs to 
define only a subset of relations.
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through webservices using BridgeDb (Additional file 1). To illustrate the usefulness of 
the standardized interface, we recreated the same functionality in a program without 
using BridgeDb (Additional file 2). In the latter case specialized code had to be written 
for each webservice, which makes the code more complex, and less flexible. For a full 
description of the API and more examples, see the developer documentation on the 
BridgeDb website [13].
BridgeREST API In addition to the Java API, we provide a REST-based interface. The 
required software can run in the background and can be embedded in non-Java applica-
tions. Each function is accessed by a URL that specifies the address of the service and 
query parameters. For example, http://localhost/Human/search/ENSG00000122375 
includes the following query parameters: ‘search’ specifies the type of query, ‘Human’ 
is the organism database being searched, and ‘ENSG00000122375’ is the query in-
put. In this example, a list of identifiers and data sources corresponding to the query 
would be returned in the form of tab-delimited plain-text. Developer documentation 
for BridgeREST is also available on the BridgeDb website [14].
Implementation of the mapping services layer
The mapping services supported by BridgeDb can be broadly categorized in three 
groups: flat files, relational databases, and online web services. Flat text files are great 
for custom annotations. Local relational databases provide the fastest access. They are 
stable and make long-running analyses repeatable. Web services are not as fast as local 
databases but potentially provide the broadest range of data and if well maintained, are 
more up-to-date. 
In addition to supporting a number of third-party mapping services, BridgeDb also 
provides its own mapping services, in the form of BridgeDerby databases for efficient 
mapping of genes, proteins and metabolites, and in the form of a webservice named 
BridgeWebservice. Thus, BridgeDb can be used as a complete identifier mapping solu-
tion out-of-the-box for common bioinformatics applications. See Table 1 for a list of 
supported mapping services and by whom they are provided.
 Additional files are available at the BMC Bioinformatics site at http://www.biomedcentral.com/1471-
2105/11/5 
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Table 1: Mapping services currently supported by BridgeDb
Description Category Provided by
Tab delimited text files Flat file Anybody
BridgeDerby for genes and 
proteins
Relational database BridgeDb (Gladstone Institute)
BridgeDerby for metabolites Relational database BridgeDb (Gladstone Institute)
EnsMart Web service European Bioinformatics Institute
PICR Web service European Bioinformatics Institute
BridgeWebservice Web service BridgeDb (Gladstone Institute)
Synergizer Web service Harvard Medical School
CRONOS Web service Helmholtz Zentrum
The BridgeDerby mapping service is based on the Derby [15] relational database man-
agement system. Its advantage is that it can be used to create local databases that consist 
of just a single file. These files can be downloaded, copied and installed easily. This 
system, along with the database schema, has been described before [3]. The schema can 
be briefly summarized as follows. Each database consists of three tables. The DataNode 
table contains a list of local identifiers plus a short two-letter abbreviation for the data 
source. The Link table contains a list of relationships between identifiers. Each link has 
a left part and a right part; each part refers to a unique data source and identifier in the 
DataNode table. Finally, the Attribute table contains symbols and other attributes for 
DataNode entries.
We create database files per species for genes and proteins. We also created a database 
file for metabolites, which is species-independent. Using the stacking mechanism, the 
metabolite database and a species-specific gene and protein database can easily be com-
bined to form a complete database for biological entities of a given species. The proce-
dures for creating these two types of database files are described below in more detail.
Ensembl-based gene and protein database files. The database files for genes and pro-
teins are based on Ensembl [16]. Relevant MySQL tables from Ensembl are locally 
installed and accessed via Ensembl’s Perl API. Identifiers, annotations and cross-refer-
ences are extracted, transformed and ultimately loaded into Apache Derby databases. 
The Derby databases are rebuilt and released after each Ensembl database release. Each 
Derby database contains information for a single species. Currently, databases are only 
produced for species of interest, including 36 different animal, plant, fungal, and bac-
terial species. However, Derby databases can readily be generated for any species sup-
ported by Ensembl or that has been effectively “ensemblized” (i.e., loaded into a data-
base schema that is compatible with Ensembl’s Perl API). Depending on the species, a 
selected subset of data sources are extracted from Ensembl and maintained in the Derby 
databases. Typically, these include Ensembl, Entrez Gene, UniProt, UniGene, RefSeq, 
miRBase, RFAM, PDB, TIGR, UCSC Genome Browser, and WikiGene, as well as a 
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representative model organism database, such as MGI, WormBase, ZFIN, EcoGene or 
TAIR, and annotations from Gene Ontology, OMIM, BioGrid, Affymetrix, Agilent, 
and Illumina. 
The same information as contained in the Derby databases is also stored in MySQL 
databases, using the same schema. This form of the data is maintained for web service 
accessibility. Practical limitations on the size of the distributed Derby databases are not 
an issue for MySQL. Thus, additional identifier systems, annotations and cross-refer-
ences can be stored in the MySQL databases. Furthermore, with greater capacity, this 
system will be able to support additional types of information such as exon, transcript, 
and protein domain alignments, polymorphisms, and homology, which are also avail-
able from Ensembl. 
Figure 3: Simplified UML Diagram of the 
BridgeDb java library. The BridgeDb.connect 
method serves as an entry point, instantiating one 
of the many IDMapper implementations. The most 
important method of IDMapper is mapID, which 
takes an Xref object as argument. An Xref is a com-
bination of an identifier String and a DataSource 
object, the latter representing an online biological 
database.
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HMDB-based metabolite database files. Currently, the database files for metabolites 
are based on HMDB Metabocards [17], because they provide free and easy-to-parse 
access to mapping information. Each Metabocard contains cross-references to CAS, 
ChEBI, PubChem and Kegg. Each metabocard is parsed by a script and identifiers are 
added to the DataNode table. Mappings between them are added to the Link table. This 
database assumes symmetry and transitivity (i.e., all identifiers on a Metabocard map to 
all other identifiers on the same card). The official name and all synonyms are stored in 
the Attribute table as symbols.
Implementation of the tool layer
Broadly speaking, BridgeDb can be useful whenever an application needs to make use of 
multiple mapping services or wants to enable the user to choose among different servic-
es. To demonstrate this, we have integrated BridgeDb into a number of bioinformatics 
tools. These implementations are described below illustrating four different occurrences 
of the identifier mapping problem.
Use Case 1: Annotating biological pathways. WikiPathways is a collection of biological 
pathways open to community curation [18]. Pathways are networks of genes, proteins 
and metabolites that serve as a model for the actual biology of a cell. Pathway compo-
nents must be properly annotated to maintain the consistency and integrity of the mod-
el for data mapping, updating and exchange. The common names of genes, proteins 
and metabolites are usually not suitable, because they can be ambiguous and can change 
over time. Identifiers from various data sources can provide exact and unambiguous 
references. BridgeDb is used by WikiPathways to provide integrated access to the most 
relevant identifiers by stacking species-specific databases for genes and proteins with a 
generic database for metabolites. The free search mechanism of BridgeDb helps curators 
find the correct identifiers for a broad range of biological entities. And BridgeDb also 
provides link-out URLs to all cross-references to help confirm the validity of an annota-
tion and access more information from primary data sources.
Use Case 2: Merging biological networks. The Network Merge plugin for Cytoscape 
[1] can align, compare and merge networks. A common scenario for Network Merge 
includes two networks that represent overlapping biological components (e.g., protein-
protein interaction networks from two different yeast two-hybrid experiments). There 
are many valid ways to annotate such networks, but to align, compare or merge them 
they must be annotated with identifiers from a single data source. To solve this prob-
lem, the Cytoscape Network Merge plugin utilized BridgeDb to unify identifiers of the 
biological entities when merging networks, so that overlaps among networks can be 
recognized.
Use Case 3: Mapping experimental data onto biological pathways. PathVisio [3] is a 
pathway visualization and analysis tool which has recently gained the capability to im-
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port genomics data and link it to pathways. To ease the process of importing biological 
datasets, BridgeDb is used to map microarray reporters to the corresponding genes and 
proteins. The standard Ensembl-derived BridgeDerby databases contain information 
about a number of common chip designs. Each identifier in the experimental data is 
mapped to an identifier in the pathway if possible, and if a match is found, that part of 
the pathway can be colored depending on the measured gene expression.
Use Case 4: Identifier translation. The CyThesaurus plugin for Cytoscape can perform 
large-scale identifier translation on biological entities in Cytoscape networks using 
BridgeDb. The plugin can be used for different purposes. For example, when multiple 
identifier sources are used in the networks of interest, this plugin can be used to translate 
different types of identifiers to a common identifier type so that identities of the biologi-
cal entities in the networks will be unified. Alternatively, to export Cytoscape networks 
for use in other tools that require different identity types, one can utilize CyThesaurus 
plugin to translate the identifiers into identifier types that other tools can understand. 
results anD DIscussIon
Once BridgeDb has been incorporated in a bioinformatics tool, it will be possible to 
choose a suitable identifier mapping solution for the job at hand. There are a few con-
siderations when choosing the right service. First, when should two identifiers map to 
one another? What is the basis for a mapping? An identifier is a reference to a database 
record about a biological entity. If two databases describe the exact same biological 
entity, then certainly the identifiers should map to each other. But most applications 
require a broader definition of identifier mapping. When aligning microarray data with 
a pathway model based on genes, for example, there is a need for mapping microarray 
reporters to genes and gene products even though these are different biological entities. 
The facile switching of mapping services makes it easy to compare them programatically. 
In a simple test we found that most web services integrated in BridgeDb are in agree-
ment to a high degree. Four different webservices were able to map successfully more 
than 80% of a set of 1000 random Affymetrix probeset identifiers. For 72% of the total 
set, the result was identical for each webservice. For a given set of 100 Ensembl gene 
identifiers, each webservice was able to map over 91%, and the identical subset was 
86% (See additional file 3). The source code of BridgeDb includes the script used for 
this comparison (See additional file 4). In short, webservices differ in coverage of species 
and identifier types, but when two webservices are both able to translate the same set of 
identifiers, they agree to a large degree.
  Additional files are available at the BMC Bioinformatics site at http://www.biomedcentral.com/1471-
2105/11/5
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A second issue that affects the choice of mapping service is a preference for local or 
remote access. The first option is more efficient in the case of high-intensity usage. 
Another advantage of a local system is that a source of data can be frozen to make analy-
sis reproducible. A local system will not change in the middle of a long-running analysis 
procedure. Alternatively, the web service approach can be more up-to-date, is centrally 
managed and requires fewer resources (disk space) from the end-user.
Theoretically, it would be good to do away with the multiplicity of biological databases 
and designate a single universal identifier for each biological entity. However, this would 
not eliminate the need for identifier mapping, as there would still be a need to relate 
different biological entities such as transcripts and reporters. That fact, combined with 
the current situation of multiple gene databases, means that we have to deal with the 
identifier mapping problem in the best possible way. We believe that standardizing on 
a framework used by several programs in unison provides a robust and extensible solu-
tion. 
Importantly, identifier mapping should be performed as late as possible in a given 
workflow or annotation scheme. Gene databases change over time as more informa-
tion becomes available. Experimental datasets, on the other hand, are fixed once the 
experiment is done. The experimental data should be annotated as closely as possible 
to the experimental conditions. Consider for example microarray data. Perez-Iratxeta 
et al.[19] have found changes to 5% of reporter annotations over a two-year timespan. 
The mapping of reporters to genes is not static, and the data should be linked directly 
to the reporter sequence that was measured rather than to a gene or genomic location. 
Replacing probe identifiers with gene identifiers in a microarray dataset would limit 
future analyses to potentially outdated associations. The importance of BridgeDb in this 
context is that experimental data can be annotated and linked in a consistent manner 
over time, ensuring that the integrity of the data is maintained while the analysis utilizes 
the most up-to-date information about genes and gene associations.
Several mapping services supported by BridgeDb are provided by us (Table 1). We con-
sider these good default choices that are applicable to a broad range of situations. The 
local databases for genes and proteins provided by BridgeDb are based on Ensembl. 
We find that Ensembl defines reliable homology-based mappings that are frequently 
updated and available for a large number of species and, thus, provides a reasonable 
default choice. However, some authors [5] have noted that high thresholds of sequence 
similarity lead to a failure to detect all correct mappings, so extra information derived 
from gene nomenclature should be used. The BridgeDb interface does not dictate what 
constitutes a correct mapping; this is determined by the underlying mapping services. 
The flexible architecture of BridgeDb makes it possible to switch to a service that em-
ploys a different basis for identifier mapping if desired.
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The BridgeDb concept derived from our experience as developers of different bioinfor-
matics tools. The Application Programming Interface (API) was designed to be used 
by multiple tools and has proven its usability for a combination of applications with 
different uses.
We believe that it is better to build identifier mapping into a tool rather than requiring 
users to perform identifier mapping manually or with separate tools. Burdening the 
researcher to perform identifier mapping ignores the problem and dramatically limits 
the usability of the tool. Relying on external solutions also introduces unknown factors 
into the workflow that can lead to unreliable analysis results. By integrating a mapping 
service directly in the bioinformatics software tools, error-prone data preparation steps 
are avoided.
Different software packages solve the identifier mapping problem in different ways. We 
propose to modularize the identifier mapping problem into a single library. This has 
several advantages. Using a shared library means that developers can pool efforts, rather 
than investing considerable effort into maintaining isolated solutions. Tools that cur-
rently do not implement identifier mapping could do so with very little effort by just 
adding a module to the project.
conclusIons
BridgeDb frees bioinformatics tools from compromising on solutions to the identifier 
mapping problem. By providing a standardized layer through which different mapping 
services can be used, BridgeDb makes it easy for tool developers to support and switch 
between multiple services. BridgeDb can also be used to combine or merge mapping 
services to support multi-omics experiments or integrate custom resources.
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aBstract
Motivation: We combined two earlier studies on prolonged starvation in mice, one 
using proteomics and one using transcriptomics technologies. We aimed to assess the 
feasibility and utility of pathway visualization as a means to integrate various types of 
omics data, and to obtain new insights in the starvation response of the gut.
Results: We found a low overall correlation between proteome and transcriptome data 
(Spearman rank correlation: 0.21). At the level of individual genes, correlation is highly 
variable. Several mRNA / protein pairs, such as ferritin and elongation factor 2, correlate 
poorly, whereas others show high correlation. At the pathway level, transcriptomics and 
proteomics data supported each other. To visualize the integrated datasets, we developed 
new plug-ins for the PathVisio program.
Availability and implementation: The PathVisio software, together with new plug-ins 
mentioned in this article, can be obtained at http://www.pathvisio.org.
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IntroDuctIon 
The intestine plays an important role in the response of the body to prolonged starva-
tion. In two previous publications, both the transcriptome [1] and the proteome [2] of 
the murine intestine was determined after 12, 24 and 72 hours of starvation. Here the 
two studies are combined and compared. The goal is twofold. First, to develop bioin-
formatics tools needed to make an integrated omics approach feasible. Second, to get a 
more comprehensive view of regulation of pathways involved in the starvation response 
of the gut.
Omics integration
Microarray technology can be used to measure the expression of thousands of genes in a 
tissue at the same time. Methods for processing, analyzing and interpreting microarray 
data are well established, and off-the-shelf microarrays are available that have enough 
capacity to measure 100% of the genes in a genome.
Not transcripts but proteins are directly involved in biological activities. Microarray 
studies adhere to the assumption that there is a correlation between transcript and pro-
tein abundance. Mediocre levels of correlation between protein and transcript abun-
dance have been reported [3-7]. A lack of correlation could have several causes such as 
variation in protein turnover rates and post-transcriptional regulation [8]. This lack of 
correlation between transcripts and proteins leads to considerable interest in measur-
ing protein expression directly. Two-dimensional gel electrophoresis (2DE), still one 
of the most common techniques for quantitative proteomics, has continued to mature 
in recent years and achieved higher standards of data quality, repeatability and protein 
identification [9].
Nevertheless, proteomics technologies have a number of disadvantages. In a standard 
2DE proteomics experiment in mammals, typically only ~100 proteins are measured 
and identified, or roughly 0.5% of the genome, far less than what is typical for micro-
array studies. Moreover, 2DE studies suffer from problems of bias. Proteins vary more 
widely than mRNA molecules in physical properties such as hydrophobicity, electric 
charge and size. The subset of proteins measured is biased towards proteins that are eas-
ily separable on 2DE and abundant enough to be identified. Protein identification is a 
bottleneck in 2DE which means that another level of bias is introduced by the choice 
of spots to identify. Usually the spots that show the clearest response to experimental 
conditions are picked first. New gel-free proteomics techniques have been developed 
that are able to measure a wider range of protein chemistries and abundances and suffer 
less from bias problems [10]. Nevertheless 2DE remains commonly used for its maturity 
and relative simplicity [9].
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As both proteomics and transcriptomics methods each have their own advantages, it 
could be beneficial to combine them. It appears that correlation at the individual gene 
level is much higher than correlation at the global level [3]. Therefore, we believe that 
integrated omics datasets must be studied on a gene-by-gene level, taking into account 
more detailed knowledge about the roles of those genes in biological pathways. Because 
the relation between genes and proteins is heterogeneous and context-dependent, we 
propose that integrated omics analysis must use available a-priori knowledge, for ex-
ample in the form of pathway diagrams. Pathway diagrams contain biological context, 
such as which entities are related, what is their cellular location, which proteins are 
interaction partners, and what is the nature of those interactions (stimulation or repres-
sion). By visualizing the combined dataset on a pathway diagram one can interpret the 
biological context more easily. As part of this study we aimed to develop easy-to-use 
software to make this possible.
Regulation of the intestinal response to fasting
The present study investigates the intestinal changes that occur in response to prolonged 
fasting. A better understanding of fasting could lead to better understanding of weight-
loss diets and better treatment of cachexia (wasting syndrome) caused by chronic disease 
[11].
Prolonged fasting leads to changes in gene and protein expression in different organs to 
sustain fuel homeostasis. A basic model for fasting response can be summarized as “sugar-
fats-proteins”, where the body switches to different food sources in order of preference 
[12]. At first, blood glucose levels are maintained mainly by glycogenolysis in the liver. 
When the hepatic glycogen store nears depletion, the body switches to gluconeogenesis 
as the main source of glucose. Gluconeogenesis is briefly fueled by muscle proteolysis, 
but then fatty acid oxidation and ketone body synthesis take over. Finally, the terminal 
phase arrives when only proteolysis can sustain glucose production. If fasting continues, 
this will eventually lead to death, usually by respiratory failure. Humans can survive up 
to 6-8 weeks without food [13]; mice can survive for 4 days.
It is clear that the various organs (liver, intestine, adipose tissue, muscle) play different 
roles in the fasting response, but the whole picture is far from completely elucidated.
The fasting state has a strong effect on the intestine. Transcriptomics studies have shown 
that two biological processes are mainly affected: cell turnover and energy metabolism. 
Enterocytes turn over rapidly during the digestive state, which represents a major energy 
expenditure. Cell turnover is progressively down-regulated during fasting, as can be 
seen from expression of genes in the cell cycle pathway. Cyclins and cyclin-dependent 
kinases are decreased, inhibitors of cyclins are increased [1]. This is accompanied with a 
decrease in the apoptosis pathway, the effect of which is also visible as a maturation of 
enterocytes [14].
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Regarding energy metabolism, it has been established that cells of the intestine prefer-
entially use glutamine and ketone bodies as energy source. During the early response, 
which peaks at 12h in mice, fat is catabolized to ketone bodies, and glutamate is ca-
tabolized to pyruvate. Glutamine, which the intestine can not produce sufficiently by 
itself, is not degraded but conserved. Pyruvate oxidation is inhibited, but is converted 
to lactate instead, to be excreted to the blood and used as a fuel for gluconeogenesis in 
the liver.
As fasting continues, a phase transition occurs, which is most clearly visible in the fatty 
acid oxidation pathway and electron transport chain. Gene expression in both pathways 
is reduced. There are indications that glucose export to the blood is increased at the 
expense of lactate production [1]. 
An open question which this study tries to answer is whether protein expression data re-
inforce the picture that arises from transcriptomics pathway analysis, and to what extent 
post-transcriptional regulation plays a role in these pathways. 
methoDs
The experimental procedure for treatment of animals, microarray and 2DE was de-
scribed before [1, 2], but will be briefly summarized here.
Animals Male FVB mice from Charles River (Maastricht, The Netherlands) were 
housed at 20-22oC, 50-60% humidity on a 12 hours light/dark cycle. They ingested 
food and water ad libitum until the age of 6 weeks. Groups of 6 mice were fasted for 0, 
12, 24, and 72 hours, after which the animals were killed by cervical dislocation. The 
small intestine was removed and separated from adjacent tissue, and both protein and 
RNA were isolated. The same individuals were used for both microarray and proteomics 
experiments.
Microarrays Samples of the intestine were applied to 60-mer Mouse Development 22k 
Oligo Microarray G4120A (Agilent). Three arrays per experimental condition were 
used. Per microarray, 20 μg mRNA, pooled from 2 intestines, was labeled with Cy3. 
RNA Pooled from 6 fed animals was labeled with Cy5 and used as a common reference 
across all arrays. After hybridization the arrays were scanned with Agilent’s dual-laser 
microarray slide scanner and processed with Agilent’s Feature Extraction software 6.1.1. 
Quantile normalization was applied to background-subtracted intensities.
2DE The procedure for generating 2D protein gel images was as described before [15]. 
Protein samples were isolated from equal quantities of proximal and distal parts of the 
intestine, pooled per mouse. 1 gel was made for each mouse. 100 μg of total protein 
was separated by isoelectric focusing using IPG strips, and then placed onto 12.5% 
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Figure 1 Protein-mRNA correlation. 
In this plot, the fold-change of protein and 
mRNA are plotted against each other. Fold-
changes are calculated for each time point 
against t=0. In cases where multiple protein 
spots correspond to the same gene, the average 
was used. The overall correlation plot shows 
that there is very little agreement between pro-
tein and gene expression.
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SDS-polyacrylamide gels for protein separation in the second dimension. Gels stained 
with SYPRO Ruby Protein stain were scanned with the Molecular Imager FX (Bio-Rad 
Laboratories).
Analysis of differentially expressed proteins was performed using PDQuest 7.3 (Bio-Rad 
Laboratories). A number of spots were selected for identification, with a preference for 
spots with a significant intensity difference. Selected spots were excised and subjected to 
tryptic in-gel digestion and MALDI-TOF MS (Waters, Manchester, UK), generating 
peptide mass fingerprints which were subsequently identified.
Microarray annotation The microarray type used was the 60-mer Mouse Development 
22k Oligo Microarray G4120A (Agilent). The microarray contains 20280 probes of 60 
nucleotides each. The annotation file provided by Agilent (Version of Dec. 16 2009) 
associates 9616 probes to Ensembl gene identifiers.
The probes were designed based on a 5-year old genome build, which could have di-
verged in the intervening years. On the assumption that 60-mer probes do not require 
a complete sequence match to hybridize to transcripts, we investigated if a blast search 
with less stringent settings would increase probe annotation coverage. We selected the 
best blast hits against the current Ensembl (release 57) Mouse cDNA database, with 
a minimum e value of 1.0e-6. The blast resulted in annotation for 10696 probes, an 
increase of 11%. We opted to employ the blast results instead of Agilent annotations 
for all further analysis. Identifiers in both data sets were mapped to pathways using the 
BridgeDb framework [16]. None of the standard identifier mapping resources included 
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a custom mapping table. The blast results were formatted so that they could be under-
stood by BridgeDb.
Analysis and Pathway visualization Correlation and expression plots were created with 
R/BioConductor. Pathway visualization was performed using the PathVisio program 
[17].
The mouse pathway set, obtained from WikiPathways [18]  March 2010, was used for 
the analysis. This pathway set covers 3975 unique genes, or 14% out of 28063 mouse 
genes and pseudo-genes known in Ensembl release 57. The pathway set covers 66% (51 
out of 77) of unique measured proteins and 24% (2083 out of 8648) of unique mea-
sured transcripts.
Figure 2 Combined mRNA and protein expres-
sion plots. These three plots show the expression of in-
dividual genes in detail. Each dot represents a measure-
ment of a spot or probe. Lines connect the average of 
each probe or spot per time point. Solid lines represent 
transcripts, dashed lines represent proteins. The aver-
age intensities at 0 hours have been normalized to 1; 
all other values are relative to this average. Top-left: 
Ferritin heavy (Fth1) and light chain (Fthl1), show-
ing opposite trends for transcript and protein expression 
levels. Top-right: Triose phosphate isomerase (Tpi1), 
which is down-regulated at 72 hours with the excep-
tion of one protein spot. Bottom: Elongation Factor 2 
(Eef2), an example of a gene that shows higher tran-
script expression but lower protein expression.
7
Figure 3: Glycolysis and Gluconeogenesis pathway in PathVisio. Each colored box represents a gene product. 
Blue indicates increased expression levels, yellow decreased. Each box is a heat map with rows representing probes 
or spots, and columns representing time points. The rightmost column is a flag that indicates if the given row is 
a protein spot (green) or microarray probe (pink). Multiple probes and/or spots can be shown in a box. Tpi1 is 
marked with the letter A.
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results
The proteomics dataset contained 130 identified spots, corresponding to 77 unique 
protein identifiers. For only 59 out of those 77, both the mRNA and protein abundance 
was determined. For each of the 59 proteins and genes, the log2 ratio was calculated 
for 12, 24 and 72 hours. When taken together, there is very little overall correlation 
between the two types of data (See Figure 1). The spearman rank correlation coefficient 
is 0.21, which indicates a slight positive overall correlation between mRNA and protein 
levels.
The picture is very different for various proteins. There are highly correlating, differ-
entially expressed transcript-protein pairs such as Vim (Vimentin), Aldob (Fructose 
Biphosphate Aldolase B) and Atp5h (ATP Synthase D chain).
On the other hand, some proteins show an opposite correlation, where the transcript is 
regulated in the opposite direction as the proteins. In most of these cases, the transcript 
is up-regulated but the corresponding protein is down-regulated, as is the case for Eef2 
(elongation factor 2, See Figure 2), Aldh1b1, Arhgdia, Hnrnpa2b1 and Uqcrc1. For 
Eef2 a similar divergence between mRNA and protein levels has been reported indepen-
dently in liver and muscle tissue [19].
Some proteins that are identified in multiple spots show varying expression in different 
isoforms of the protein. This indicates that post-translational modifications could play 
a role to regulate protein activity. The proteins that are potentially under post-trans-
lational regulation include metabolic enzymes (Tpi1 and Atp5h), proteins related to 
protein folding (Calr, Hspa8 and Hspa5) and cytoskeletal proteins (Krt19, Actb, Actg2 
and Vil1). 
software ImPlementatIon
PathVisio has a plug-in framework to allow customization to new types of pathway 
analysis and visualization. To visualize protein and gene expression data side-by-side in 
pathway context, we developed two new plug-ins for PathVisio: the Gex plug-in, which 
manages data visualization, and the BridgeDbConfig plug-in, which enables configura-
tion of identifier mapping resources. The Gex plug-in is now a core plug-in that is a part 
of the main distribution since the release of PathVisio 2.0, the BridgeDbConfig plug-in 
is installed separately.
High-throughput datasets in tab-delimited text format are imported using the expres-
sion data import wizard which is part of the Gex plug-in. Data should already be nor-
malized and preferably log-transformed before data import. During data import, the 
user can select which column contains identifiers for genes or proteins. A prerequisite 
for integration of multiple omics studies is the ability to map identifiers from various 
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sources [20]. In this case, each data point in the microarray dataset is identified with an 
Agilent probe identifier (such as A_65_P03556), and proteins were associated with a 
Uniprot identifier (such as P09528). PathVisio allows direct import of mixed identifiers 
without the need to pre-process the data.
The BridgeDb framework [16], which is incorporated into PathVisio, was used to map 
probe and protein identifiers to gene identifiers and integrate these two datasets. 
Three proteins were annotated with erroneous protein identifiers by the identification 
software (in one case a GenBank accession number, in one case an identifier for the hu-
man homologue, and in one case a deprecated Uniprot identifier). Rather than fixing 
the original data, BridgeDb allowed us to create a separate “manual override” mapping 
table and combine it with the rest of the mapping resources. The advantage of doing 
this, rather than simply fixing up the original dataset, is that the modifications remain 
separate and can be more easily re-examined or reverted in the future.
Thus three sources of mapping information were used; first the results of BLAST of mi-
croarray sequences for mapping Agilent probes to genes, second a regular BridgeDerby 
database for mapping proteins to genes, and third a manual override table to fix errors. 
Using BridgeDb, the three resources were unified into a single mapping resource.
After the data import step, the user configures how the data is represented by colors. 
This can be done either using Boolean expressions, or by mapping numerical values to 
a color gradient. These colors are then displayed in the gene boxes. Multiple conditions 
can be displayed side-by-side.
One feature that is of particular interest for omics integration is the fact that if multiple 
rows of data map to the same gene box, they can be averaged and mapped to a single 
color, or the box can be divided horizontally and each row in the dataset gets it own 
row in the box. The problem of a variable number of data points per gene box occurs 
sometimes with microarrays that have more than one probe per gene, but it is especially 
important for omics integration where one is often dealing with two datasets of very 
unequal size (in this case 130 proteins versus 10696 transcripts), which automatically 
means that some boxes have more data than others. The box is divided horizontally for 
each corresponding row in the dataset. Thus, the box is used as a small heat map rep-
resentation of a subset of the data, where each column represents a condition and each 
row represents a probe. 
Although this subdivision means that the boxes can get cramped, we find this approach 
is superior to summarizing data, because that would mean throwing away data. See for 
example Tpi1 in Figure 3, where two rows are clearly differentially expressed. Boxes 
can be enlarged manually if necessary. Data can be visualized in parallel for direct com-
parison, but it is also possible to create separate visualizations and toggle between them 
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using a drop-down list. Sometimes visualizing different time points separately leads to 
less confusion and makes it less likely that the response of one gene in the first time 
point is erroneously compared to another gene in the last time point. Separating the 
time points in different visualizations also helps to combat the information overload in 
a single box.
DIscussIon
The combination of proteomics and transcriptomics data provides us more information 
than just one of the two datasets on its own. Global correlation is not high, but on a 
gene-by-gene level we see a very varied picture. Genes that do not show high correlation 
present leads for investigation into post-transcriptional regulation.
Although proteomics data has fewer data points than transcriptomics data, there are a 
few instances where important transcripts are not measured, due to absence of a suit-
able probe on the array. In those cases, protein measurements can fill important gaps 
in pathways. In the urea cycle, no mRNA expression levels were measured for otc2 
(ornithine carbamoyltransferase) and arg2 (arginase-2) genes (due to absence of probes 
for these genes on the microarray). Nevertheless, protein levels for these genes have 
been measured showing a clear down-regulation, in particular in the early (12 hours) 
response. This is consistent with glutamine conservation which is also demonstrated by 
the expression of genes such as Oat, PycS, Gls and GlnS.
Similarly, the down-regulation of Acaa2 (only measured as protein) is completely consis-
tent with the reduction of fatty acid biosynthesis, also supported by the down-regulation 
of genes such as Hadh1. Additionally, down-regulation of the Gapdh protein, indicating 
a decrease in glycolysis activity, is entirely consistent with strong expression of the Pck1 
gene, a gateway for gluconeogenesis (see Figure 3).
Analysis of the transcriptome has revealed strong effects on cell cycle regulation and 
apoptosis. In particular cyclins are decreased in expression. Cell turnover in intestine is 
thought to be a major source of energy expenditure. Unfortunately, it must be noted 
that no cyclins or other proteins related to cell cycle regulation and apoptosis have been 
identified, most likely because they are not abundant enough to be detected using the 
2DE technique. The comparison of the two datasets clearly reveals the bias problems 
occurring with proteomics techniques. Proteomics analysis alone would have missed a 
major regulatory effect of starvation in the gut.
Different phosphorylation states lead to different spots in a 2D gel, thus a change in 
such a spot could mean two things: the experimental condition has led to a change in 
total quantity of the corresponding protein, or it has led to a change in the state of the 
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protein (or both). Due to the incompleteness of proteomics data, these two cases cannot 
be distinguished. A change at the spot level is interesting, but a decrease cannot always 
be straightforwardly interpreted as a decrease in functional activity.
A clear example of differentiation at the spot level is Tpi1 (Triose phosphate isomerase), 
an important enzyme of the gluconeogenesis pathway, which is increased in spot 3220 
but decreased in spots 6307 and 7312 throughout the fasting period (See Figure 2). 
From the estimated mass as well as the mass spectrum it appears that the protein in 
spot 3220 is missing an N-terminal fragment. Possibly alternative splicing or proteolysis 
plays a role in the regulation of this protein. Assuming that the partial Tpi1 protein has 
a reduced activity, this finding is consistent with a reduced activity in the glycolysis path-
way. However, to determine the exact nature of the observed change in Tpi1, follow-up 
experiments will be necessary.
Another protein that is affected in an interesting way is ferritin, a protein that is neces-
sary for the storage of iron in tissues. Ferritin is down-regulated at the gene level, but 
up-regulated at the protein level throughout starvation (See Figure 2). Note that this is 
the case for both ferritin heavy chain and ferritin light chain. Because iron from food 
intake is drastically reduced, the decreased mRNA expression level of ferritin is unsur-
prising. Harder to explain is the increased protein abundance in spite of lower transcript 
levels. It has been shown that mRNA turnover regulated by the iron responsive element 
binding protein (Ireb2, not measured in this study) has a strong effect on ferritin [21], 
which could explain the discrepancy between protein and mRNA abundance. Another 
possible explanation is that the increased values are caused by a change occurring in 
erythrocytes, which can never be fully excluded from the protein sample. Other causes, 
such as the presence of other ferritin spots in the gel that have not yet been identified, 
can not be ruled out.
This comparison illustrates that the 2DE technique by itself does not provide enough 
data for a systems biology level overview. In this study, if only proteomics data had 
been available, important pathways such as apoptosis and cell cycle regulation would 
have been missed entirely. Nevertheless, protein expression data do provide interesting 
insights into regulation on a gene-by-gene basis. In particular those proteins that do not 
correlate well are interesting, at the very least for generating hypotheses for follow-up 
experiments.
A number of existing applications can perform visualization of high-throughput data-
sets, such as KEGG Atlas [22], ProMeTra [23], Vanted [24] and Reactome SkyPainter 
[25], and reviewed in [26, 27]. Only some of those have demonstrated the capability 
to perform pathway visualization with multiple omics datasets at the same time, such 
as ProMeTra, which is focused on combining metabolomics and transcriptomics data. 
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The automated mapping of mixed identifiers is a distinguishing feature of PathVisio that 
makes it particularly suited for integration and simultaneous visualization of datasets 
from different sources.
In conclusion, proteomics data sometimes reinforces the conclusions made from tran-
scriptomics data, and sometimes poses new questions. The interpretation is not straight-
forward, and the correlation of gene and protein expression levels (or lack thereof ) must 
be interpreted on a case-by-case basis. Pathway visualization can serve as a useful aid, 
because pathways serve as a knowledge base for a broad collection of biological informa-
tion.
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The field of pathway visualization is currently undergoing strong development. Years 
of research have led to detailed knowledge on pathways. Online pathway databases are 
increasing in size; Reactome reported 2.7-fold increase in 3 years [1], and KEGG added 
50 pathways in 2 years [2]. New standards and tools are being developed to get informa-
tion out of those databases, and at the same time, the wiki model is starting to be used 
for online collaboration to get data into those databases [3]. With the efforts around 
Molecular Interaction Maps (MIM) [4] and the Systems Biology Graphical Notation 
(SBGN), pathway notations are becoming standardized in the same way they have been 
in electronic circuit diagrams and Unified Modeling Language (UML) diagrams for 
object oriented programming [5].
The goal of this thesis, as stated in chapter 1, is to develop methods to integrate mul-
tiple types of experimental data and visualize them on pathway diagrams. To achieve this 
goal, PathVisio, WikiPathways and BridgeDb were developed. As shown in chapter 3, 
PathVisio can be used to create pathways manually. In chapter 4 we have seen how path-
ways can be shared and curated collaboratively on WikiPathways. The WikiPathways 
resource uses the wiki model to lower the barrier to entry and attract contributing scien-
tists. At the same time, safeguards are in place to monitor additions and ensure a mini-
mum quality level. Chapter 5 demonstrated how BridgeDb provides a generic frame-
work for the identifier mapping problem. Identifier mapping is crucial to the integration 
of diverse datasets. Finally, chapter 6 illustrated how all these pieces fit together to enable 
integration of multiple high-throughput datasets and visualization on pathways.
A number of new software tools are presented in this thesis, namely PathVisio, BridgeDb 
and WikiPathways. But the question remains: what advantages do they provide com-
pared to similar tools? How do these tools work together with other bioinformatics 
software? How will they be further developed in the future?
In this chapter, we will critically evaluate these tools and compare them to other bioin-
formatics software, based on these aspects: the ability to aid in data interpretation, the 
ability to perform data integration, the role in analysis pipelines, the possibilities for 
code re-use, the adherence to common standards and the relation to open access and 
open source philosophies. For each aspect, we will identify strong points of our software 
framework, as well as criticism and potential future improvements. In this discussion we 
will also draw lessons that could benefit the field of bioinformatics as a whole.
Data InterPretatIon
Simply sifting through lists of differentially expressed genes in spreadsheets is a very 
limiting method of data analysis. Many alternative methods have been developed for the 
interpretation of high-throughput datasets. These approaches fall into two categories: 
data-driven and knowledge-driven [6]. In data-driven interpretation, the dataset is ana-
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lyzed by itself, for example using various clustering methods [7] or principal component 
analysis (PCA). Knowledge-driven approaches use existing biological knowledge as basis 
for further analysis. 
Different types of knowledge can be used for knowledge-driven interpretation. This 
thesis focused on pathway visualization, i.e. projecting the data on manually curated 
pathway diagrams. PathVisio is one of several tools that can do that. Biological networks 
are another possible source of knowledge. There are many types of biological networks, 
such as protein-protein interaction networks, co-citation networks and co-expression 
networks. Network and pathway analysis tools are described in several review articles 
[8-11]. Another type of knowledge that can be used are ontologies, in particular the 
Gene Ontology [12]. Much of the wide variety of ontological analysis tools is reviewed 
in [13]. Finally information about the promoter sequences of genes may be used as 
knowledge source. See Table 1 for a list of software options for each type of knowledge 
analysis.
Table 1: A non-exhaustive list of types of knowledge-driven analysis and the bioinformatics software that can 
perform them.
Knowledge type Software options
Pathway diagrams PathVisio (chapter 3) 
GenMAPP [14] 
Reactome SkyPainter [1] 
CellDesigner [15] 
KEGG atlas [16]
Interaction, co-citation and co-ex-
pression networks
Vanted [17] 
Visant [18] 
GENeVis [19] 
Cytoscape [20]
Gene Ontology GO-Elite [21] 
DAVID [22] 
BiNGO [23]  
Onto-Tools [24]
Promoter sequences Genomatix [25]
Data-driven approaches work best when the experimental effects are clear-cut and easily 
separable in clusters. Knowledge-driven approaches are better at distinguishing subtle ef-
fects [6]. For example, if multiple genes are differentially expressed consistently through-
out a pathway, then the added effect is interesting, even if the individual fold-changes 
are very low. The disadvantage of knowledge-driven approaches is that they depend on 
the quality of annotation. If annotation is lacking, effects may be missed. The choice for 
either data-driven or knowledge-driven may depend on the study subject. For example, 
in many nutrition studies only subtle changes in gene expression are found, making 
knowledge-driven approaches more suitable. 
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PathVisio and WikiPathways clearly have a focus on pathway knowledge. The pathway 
level of knowledge is attractive because of its intuitiveness, ease of interpretation and 
ability to map diverse pieces of data, including not only the functional grouping of 
biomolecules, but also the order of interaction, complex formation, compartmentaliza-
tion and localization, links to literature and online bioinformatics resources. All of these 
diverse pieces of information can be brought together in a single picture. Networks are 
harder to visualize, because of the difficulty of automatically generating a good layout 
(chapter 2). This makes pathway visualization programs easier to use and more user-
friendly, which is a strong point of PathVisio.
The choice for pathway visualization is not exclusive. The interpretation approaches 
mentioned above are all complimentary, and many can be applied to the same study in 
addition to pathway analysis. Each method could give rise to distinct results. Re-inter-
pretation of a published dataset using a different approach can give rise to new insights 
[6]. The study presented in chapter 6 is an example of this, as it is based on two datasets 
that were published previously.
A shortcoming of PathVisio is that it can make use of only one type of knowledge. 
GenMAPP and Cytoscape (through the BiNGO plug-in) can perform ontological anal-
ysis in addition to their core functionality. In the future, plug-ins could be developed for 
PathVisio for ontological analysis, to make it a more versatile tool for knowledge-driven 
interpretation.
Data IntegratIon
There are several published studies that integrate multiple omics datasets, reviewed in 
[26, 27]. In addition, numerous studies using pathway visualization have been pub-
lished. Studies that combine both multi-omics datasets with pathway visualization are 
currently not very common. Undoubtedly more will appear in the future as both the 
required software tools and the experimental technologies are maturing rapidly. A recent 
publication combines pathways with both transcriptomics and metabolomics data, us-
ing the online ProMeTra tool [28]. Although not demonstrated in this thesis, PathVisio 
is capable of mapping and displaying metabolomics data as well, and applying this to 
a real dataset will make an interesting topic for a future study. PathVisio could still be 
improved specifically for metabolomics data visualization. Metabolomics data is often 
obtained from excreted body fluids (for example blood or urine), where metabolite con-
centrations differ from concentrations inside the cell. Visualizing extracellular measure-
ments on pathways as though they were measured inside the cell is a false presentation. 
To map metabolomics data correctly, PathVisio will have to be adapted to distinguish 
cellular and extra-cellular metabolites.
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Merging multiple datasets often leads to a problem of mapping mixed identifiers [29]. 
An important advantage of PathVisio is the flexible identifier mapping enabled through 
BridgeDb. This makes PathVisio well suited to visualize multiple datasets directly side 
by side. The flexibility of BridgeDb to switch between identifier mapping services means 
that it will be easy to adapt PathVisio to new experimental methods in the future (chap-
ter 5). 
analysIs work flows
How is bioinformatics software used to analyze high-throughput experiments? Using 
microarray data as an example, we can identify a number of steps that are fairly stan-
dard [6]. The first step is to extract raw data from the experiment. In a second step, 
quality control is performed, filtering out low quality data and possibly repeating parts 
of the experiment that were substandard. Third, data is normalized to filter out techni-
cal sources of variation, leaving only biological variation in the data. Fourth, statistical 
analysis is used to find meaningful differences between the conditions compared, taking 
into account the multiple testing problem. In the fifth step we take the complete dataset 
and visualize or transform it in such a way that biological interpretation can take place. 
For each step in this work flow, different software tools can be used. The first and second 
steps are very dependent on the technology in question. In the case of microarrays, raw 
data is extracted by fluorescent scanning of a glass slide. Vendor software will localize 
spots and estimate raw intensities from the scanned images. There are a number of op-
tions for data normalization, depending on the microarray platform used, with quan-
tile normalization commonly used for two-color arrays and Robust Multi-chip Average 
(RMA) for one-color arrays. A number of statistical tests, such as Student’s t-test or 
Analysis of Variance (ANOVA), can be used in step four, followed by a multiple testing 
correction methods such as False Discovery Rate (FDR).
Table 2: Examples of software used in analysis workflows
Workflow step Examples of software
Raw data extraction Vendor Software (Affymetrix GCOS, Agilent feature extraction soft-
ware)
Quality Control Vendor software, R/BioConductor, Spotfire
Normalization R/BioConductor, Microsoft Excel
Statistical Analysis R/BioConductor, Microsoft Excel
Interpretation GenMAPP, Cytoscape, PathVisio, Vanted
Some of the tools mentioned in Table 2 are comprehensive and can perform sev-
eral or all steps without the need to switch to a different software package. From 
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the perspective of user-friendliness, it is better to do as many steps as possible 
within the same software environment, as each switch usually involves the need 
to adjust data and to familiarize oneself with new software.
A shortcoming of PathVisio is that it is insufficient by itself, to perform a com-
plete workflow from start to end. PathVisio deals only with the final interpre-
tation step of this workflow, and assumes statistical analysis has already been 
applied using different software. The need to switch between software environ-
ments during analysis is a clear downside of PathVisio, and could be improved 
in the future. It would be an interesting possibility to allow t-tests, analysis of 
variance and multiple-testing corrections to be applied within the PathVisio en-
vironment, thereby integrating statistical analysis (step four).
Comprehensive tools that integrate the whole analysis pipeline are an improve-
ment from the viewpoint of user-friendliness. On the other hand, from the per-
spective of analysis power, it is important to retain the possibility to switch to 
a different tool between every step. Especially when dealing with new analysis 
methods, new experimental designs or new technologies, it is unlikely that they 
are supported well, and the more general the software package, the less likely it is 
adapted to specialized circumstances. So while it is good to strive for comprehen-
siveness, it is important to create exit and entry points before and after every step 
of the analysis workflow. At the moment, PathVisio reads expression datasets in 
tab-delimited text format, with very few restrictions on the formatting of rows 
and columns. This format was chosen because it is supported by a large number 
of tools. Nevertheless, tab-delimited text is often the lowest common denomi-
nator. Software packages often have different preferred formats, tab-delimited 
text is provided as an export option, usually with some data loss. In the future, 
PathVisio should be improved to support more data formats generated by tools 
for statistical analysis. If statistical analysis was done using R scripts, PathVisio 
could read the binary format of R directly. PathVisio should be able to read XLS 
files generated when the statistical analysis is done in Microsoft Excel. Plug-ins 
could be developed in the future to read these formats and make switching more 
user-friendly.
moDularIty anD coDe re-use
The previous sections listed a large number of tools for analysis and interpretation of 
high-throughput datasets. Clearly there is an abundance of tools available in the field 
of bioinformatics. Generally each tool has a distinguishing feature that gives it reason 
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for continued development. In the crowded space of bioinformatics applications, bio-
informatics developers compete for scarce resources such as funding, attraction of other 
developers and user attention. Thus a type of natural selection takes place. As long as 
there is no “killer-application” that has all important features, a stable equilibrium may 
exist where multiple tools can occupy a niche that serves a public need, while none of 
them can gain complete dominance.
From the point of view of science as a whole, is this abundance of tools a good thing? 
The large selection could be considered a blessing of choice and flexibility, but is also 
a nuisance, for several reasons [30]. One reason, as mentioned in the previous section, 
the transition of one tool to another often involves usability problems and requires re-
formatting of data. Discoverability is another problem; a good tool may exist that can 
perform the analysis that you need, but it is hard to find amongst all choices. Tools vary 
widely in quality, which means that a search for them leads to results with a low signal-
to-noise ratio. Small tools may never gain the necessary mindshare, meaning that it is 
not known by the people who could make good use of it.
We may hope for a convergence to happen, where user attention, developer attention 
and funding resources come together around a small number of big projects instead a 
large number of small ones. But this may never happen for several reasons. First, as men-
tioned before, newly developed tools may be better suited for new methods or new ex-
perimental technologies. This means that there will be a continuing need for specialized 
tools. Second, convergence may not happen because large development projects have a 
huge communication overhead that creates a high risk of running late and missing goals 
[31]. This does not mean that large projects are impossible, but it does mean that small 
projects have an inherent selection advantage in the evolution of bioinformatics software 
applications. Third, there is no consensus around development technologies (such as e.g. 
choice of programming language, redistribution license, operating system, GUI toolkit, 
or development framework), which severely limits the possibilities for convergence. For 
example, BioPerl [32] and BioConductor [33] are two large, successful bioinformatics 
projects, the former written in Perl and the latter in R, that can not easily share code 
with each other or with, for instance, PathVisio, which is written in Java. Even if coop-
eration across the boundaries of programming languages is possible, it always requires 
extra work. Because each programming language has its own strengths and weaknesses, 
it is unlikely that we will see a convergence around one. Java for example, is good at pro-
viding cross-platform programs with a user-friendly GUI, and provides ways to struc-
ture large code bases, but is less flexible than interpreted languages.
The question should not be what we can do to overturn the existing reality of continuing 
development of niche bioinformatics applications, but what we can do within the given 
situation to achieve the most desirable outcome.
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A possible solution is to focus on maximizing the rate of code re-use. It may not be 
realistic to expect developers to voluntarily stop developing new tools, but it might be 
feasible to facilitate more sharing of code, so that a larger set of features is included in 
even the smallest tools. Each shared module then forms a building block for large ap-
plications. Another side effect of code re-use is that it facilitates user-friendly transitions 
between tools, because if modules are shared then this makes transfer of data from one 
tool to the next easier, without the need for re-formatting data files. 
Which parts of code are most amenable to re-use? A software project can be thought 
of as a large number of modules, some modules requiring the functionality of other 
modules to work. Thus, a dependency tree can be drawn, a directed graph where edges 
represent a dependency of one module on another. For example, see Figure 1 to see 
the dependency tree of BridgeDb and PathVisio combined. This dependency tree is 
evolving as both projects continue development. Modules at the top depend on almost 
everything else; modules at the bottom depend only on the programming environment. 
PathVisio can be split into four main modules, and a number of smaller modules (called 
plug-ins).
Modules can be shared by two software projects only if the modules that they depend 
on are shared as well. This usually means that modules with the fewest dependencies are 
most amenable to sharing. As can be seen from this figure, the next module that could 
be most easily re-used is the PathVisio core module, because it only depends on libraries 
external to PathVisio project. The PathVisio user-interface module can only be re-used if 
the PathVisio core module is re-used as well. Plug-ins in PathVisio are actually the least 
amenable to re-use, because they depend on all other PathVisio modules and thus carry 
a large dependency load. 
The PathVisio core module contains support for reading and writing GPML format, 
thus re-use of this module could allow other applications to add GPML support easily. 
The Cytoscape GPML plug-in already works that way. Future efforts could be directed 
to streamline the core module to make it another independent code library.
The modular structure of PathVisio is a strong point. The separation of modules fa-
cilitated the separation of BridgeDb as an independent code library. Before BridgeDb 
started life, it already existed as one of the modules of PathVisio itself. Identifier map-
ping, which is a distinguishing feature of PathVisio, was abstracted out in the form of a 
software library component. We decided to extract the identifier mapping functionality 
of PathVisio into a separate project, mainly as an experiment to share code between 
projects, to encourage code re-use. Currently BridgeDb is being used by Cytoscape and 
PathVisio, but more may follow in the future. Thus the experiment can be considered 
successful. Hopefully, more components of bioinformatics software can be identified 
that are amenable to code re-use in a similar way.
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The recently started effort to create a standard library for SBGN using tools called 
LibSBGN can be seen as another effort in this direction. There is a large number of 
tools that support drawing in SBGN format, including CellDesigner [15], Vanted [17] 
and the Edinburgh Pathway Editor [34]. Even though these tools have an overlapping 
feature set, there is currently very little code shared. The hope is that a central LibSBGN 
module, co-developed by all tool developers, would improve this situation. LibSBGN 
could develop as a library for sharing diagrams using SBGN notation. A core module 
of LibSBGN would enable import and export to a valid SBGN file format, whereas 
Figure 1: dependency tree for PathVisio and BridgeDb modules. Java libraries and components provided 
externally are represented by rounded rectangles, BridgeDb modules are represented by hexagons, main PathVisio 
modules are represented by rectangles and PathVisio plug-ins are represented by ovals. Absolute dependencies (i.e. 
at compilation time) are marked with solid arrows, and transient dependencies (i.e. at run time) are marked with 
dashed arrows.
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other modules higher up in the dependency chain could perform automated layouts, 
rule based validation and other interesting features that could be shared by a number of 
projects. When the LibSBGN library comes to fruition, incorporating it in PathVisio 
will be an important future improvement.
stanDarDs anD software IntegratIon
Standardization efforts play an important role in bioinformatics. Bioinformatics studies 
are often based on complex workflows involving multiple databases and tools. Different 
software components must work well together to make workflows user-friendly and 
repeatable without errors. To this end, standards are being developed [35].
What is a standard? To enable cooperation, a detailed specification of something may be 
needed, be it an Application Programming Interface (API), a webservice, a computer file 
format or a programming language. When such a specification is accepted and used by 
many people around the world, it can be called a standard. Standards can be developed 
by international standards organizations, they can be developed by a community of 
stakeholders, or they can arise as de-facto standards through a dominant market share 
[36]. For example, the FASTA format was adopted by many sequence databases because 
of its simplicity, and therefore arose as a de-facto standard [37].
SBML and BioPAX are examples of standards that are developed by communities. 
SBML has been very successfully developed this way. The editorial committee of SBML 
has been very careful to include a large community of users. This has ensured that the 
imagined use cases of SBML match the actual need. SBML is successfully standardized, 
with support by multiple tools [38, 39]. The BioPAX standard has been developed in 
a similar way [38]. A disadvantage of community-based standard development is that 
progress is usually slow. Because of the large number of people involved, communica-
tion overhead is equally large. 
PathVisio and WikiPathways integrate naturally with each other because they are based 
on the same code and use the same file format. Cytoscape integrates well with both 
projects using the GPML plug-in, which also shares part of the PathVisio code base. 
The GPML file format was derived from the GenMAPP MAPP format and improved 
in practice. But GPML is not an accepted standard outside a core group of contributors. 
This makes the use of GPML limited. A valid criticism of WikiPathways and PathVisio 
is that neither support standard pathway formats such as BioPAX and SBML. This ham-
pers cooperation with other pathway tools. In the future, plug-ins should be developed 
to add support for these standards to PathVisio. 
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oPen source DeveloPment
Open source, as defined by the Open Source Initiative (OSI), means software for which 
the source code is available to anyone to examine, improve and redistribute, without 
legal restrictions [40]. Open source enables the free exchange of ideas, encoded in soft-
ware. The open sources principles are aligned with the ideals of science to “stand on the 
shoulders of giants”. The advantages of open source software are numerous [41, 42], 
including:
1. Open source is a prerequisite for maximal re-use of code. 
As mentioned before, code re-use should be encouraged in the field of bioin-
formatics. An important prerequisite for code re-use is the absence of legal re-
strictions. Developers of bioinformatics applications will avoid the use of code 
libraries that cannot be redistributed together with the application. For exam-
ple, the popular Gene Set Enrichment Analysis tool [43] is written in Java and 
freely available. Unfortunately, the associated license only permits personal 
use, which is not enough to qualify as Open Source under the criteria of the 
OSI, and would prevent redistribution in another software package. If in the 
future we want to add a Gene Set Enrichment Analysis feature to PathVisio, 
the functionality would have to be re-implemented.
2. Open source makes it possible to share the load of maintaining and updating soft-
ware. 
If code modules are shared between developers from different groups, they can 
pool efforts to maintain and update that code. For example, developers from 
the BioPerl project [32] share the work of maintaining parsers for output of 
the blast program (which used to change frequently) [30].
3. The absence of legal restrictions and hidden commercial interests encourage com-
munity formation. 
With open source licenses, outsiders have nearly the same rights on the source 
code as the copyright owners. This creates a level playing field, which gives 
outsiders an interest in further improving the code. Thus, open source can 
attract developers, leading to the formation of a community with shared inter-
ests in the software.
The source code of PathVisio, BridgeDb and WikiPathways was published under the 
Apache 2.0 License, a permissive open source license. This is an important advantage in 
comparison to commercial or restricted bioinformatics software.
In recent years, the government of the Netherlands has increasingly called for valoriza-
tion of academic research, by which is meant that the results of academic research should 
be used to create intellectual property for start-up companies [44]. This goal is mod-
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eled after the successful development of companies in Silicon Valley around academic 
research, in particular at Stanford University. Open source development is sometimes 
perceived to be at odds with the goal of valorization, and this is a potential criticism 
of PathVisio. To counter this criticism, it must be noted that there exist valid business 
models around open source software, such as dual-licensing, using software as a loss-
leader and selling software-as-a-service [42]. In those business models, the advantages 
of open source development outlined above offset the missing direct licensing revenue 
of shrink-wrapped software. Therefore open source software development is not at odds 
with valorization.
oPen access
The advantages of open access to knowledge and data are very similar to the advantages 
of open source. In parallel to the three advantages of open source discussed in the previ-
ous section we can identify:
1. Open access allows knowledge to be re-used for new purposes. 
Open access does not just mean unrestricted access to data; it also means 
the ability to create derivative works [45]. To maximize the usefulness of the 
WikiPathways collection, we want to avoid legal restrictions that form disin-
centives to new ideas for pathway analysis. The most interesting uses for path-
ways have probably not yet been imagined [46]. 
2. Open access makes it possible to share the load of updating and curating data. 
The primary reason for developing WikiPathways was the difficulty of updat-
ing the GenMAPP pathway collection to new research findings (chapter 4). 
WikiPathways aims to attract researchers to contribute fixes and updates. 
Through the creative commons license, contributors know that their work will 
be properly credited, but also that it will benefit everybody, not just the own-
ers of WikiPathways.
3. The absence of legal restrictions and hidden commercial interests encourage com-
munity formation. 
It is beneficial to WikiPathways to have a community of curators that is as 
large as possible. The creative commons license ensures that everybody has the 
ability to copy the content of WikiPathways and use it as they see fit. If some-
day in the future WikiPathways takes a direction that is not approved by the 
community, they retain the right to create a so called “fork”, meaning to copy 
the data and develop in a different direction. The existence of this possibility is 
necessary to build trust, without which outsiders would not invest their valu-
able time [46].
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WikiPathways can be seen as the antidote against commercial pathway databases. For 
WikiPathways we made a clear and explicit choice to publish all data under the Creative 
Commons attribution license. This license ensures that authors are credited, but creates 
no legal restrictions otherwise. This license was recommended by Science Commons 
[47], an organization that promotes unrestricted sharing of scientific data. The cre-
ative commons license affords the most freedoms (the only way to be more open is 
by dropping the attribution requirement, but attribution is an important motivator, 
especially in academia). The non-commercial clause would limit the possibility to make 
use of WikiPathways data in commercial tools. We believe that being able to combine 
WikiPathways data with commercial tools would actually encourage users of those com-
mercial tools to contribute back to WikiPathways. The share-alike clause is less harmful 
but complicated and may instill confusion in users. We believe that making the terms of 
use explicit is an advantage of WikiPathways. 
In the same spirit, all published articles in this thesis are open access publications.
fInal worDs
Life is incredibly complicated at the molecular level, and cannot be simplified. Through 
natural selection, life is optimized for fitness, not for understandability or ease of analy-
sis. This makes it challenging to study complex nutritional disorders, such as type II 
diabetes, which are more and more prevalent in modern society.
The role of bioinformatics is to canalize the streams of data that exist in the post-genom-
ic era. The toolset described in this thesis provides the means to tackle multiple aspects 
of this challenge. Pathway visualization with PathVisio makes it possible to see the data 
in an understandable context. Identifier mapping with BridgeDb can integrate different 
datasets. And as data turns into knowledge, it will be fed back again as a fresh new piece 
of pathway information in WikiPathways.
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2DE Two-Dimensional Gel Electrophoresis
AF Activity Flow
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BioPAX Biological Pathway Exchange
DDO Data-driven objective
Eef2 Elongation factor 2
eMIM electronic Molecular Interaction Maps
ER Entity Relationships
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Fth1 Ferritin Heavy chain 1
Ftl1 Ferritin Light chain 1
GenMAPP Gene Map and Pathway Profiler
GPML GenMAPP Pathway Markup Language
GSEA Gene Set Enrichment Analysis
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HTML Hypertext Markup Language
JDBC Java Database Connectivity
KDO Knowledge-driven objective
KEGG Kyoto Encyclopedia of Genes and Genomes
KGML KEGG Markup Language
MIM Molecular Interaction Map
MIRIAM Minimal Information Required for the Annotation of Models
NCI-Nature PID National Cancer Institute – Nature Pathway Interaction Database
OWL Web Ontology Language
PCA Principal Component Analysis
PD Process Description
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SBGN Systems Biology Graphical Notation
SBML Systems Biology Markup Language
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Tpi1 Triose phosphate isomerase
UML Unified Modeling Language
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One of the reasons we study biology is to find cures for diseases. Some diseases are 
harder to study than others. Take for example cancer, a disease that has a big impact 
on public health, and consequently a lot of time and money is invested in researching 
it. But in spite of decades of research, we still do not understand enough of what goes 
wrong in a cancer cell, and we cannot always cure it. 
Diseases such as cancer, and type II diabetes is another example, are what we might call 
complex diseases. The reason that they are so difficult to understand is that so many fac-
tors are involved. Inheritance, nutrition and lifestyle all play a role. There is not just one 
thing that goes wrong. A single inherited cancer gene is not enough to cause cancer, but 
it increases the risk. A single milkshake is not enough to cause diabetes, but a lifetime of 
overconsumption certainly does not help.
Complex diseases involve many genes, proteins and biochemicals. To better understand 
this, researchers have been trying, and succeeding, to measure anything and everything 
inside cells. In modern experiments, the activity of tens of thousands of genes can be 
measured at the same time. With all these measurements it is possible to completely 
characterize the state of a cell or tissue sample. 
With so many measurements being done, it is very important to have good tools to ana-
lyze them. This is where bioinformatics comes in. Very broadly speaking, you could say 
that the goal of bioinformatics is to analyze biological data using computers. And when 
we measure different types of molecules, such as proteins and transcripts, we do not just 
have to analyze the data, we have to combine the different types in a single analysis. This 
is what we might call data integration.
In this thesis I have looked specifically at a set of analysis methods based on biological 
pathways. What is a pathway? Processes in the cell often form chains of reactions. For 
example, sugar molecules that are used as fuel for cells are not consumed all at once. 
This process takes place in several steps. First, a couple of enzymes prepare the molecule 
to be broken down, by adding chemical groups to energize it. When the sugar molecule 
is loosened up enough, another enzyme comes in and chops it in two. The two halves 
are then further processed by other enzymes still until there is nothing left. All these 
steps together form a pathway. Pathways are easiest to explain using pathway diagrams. 
Pathway diagrams are a little bit like the blue prints of cellular machinery. They clarify 
the roles of components and make their relations understandable.
By taking these two pieces, namely pathway diagrams and data integration together, we 
can formulate the main goal of this thesis, which is as follows:
Goal: develop methods to integrate multiple types of experimental data and visualize them 
on pathway diagrams.
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PathvIsIo
Pathway diagrams are easy to make. In the example given above, you could draw the 
sugar molecules and the enzymes as circles, and the chemical reactions as lines connect-
ing the circles.
Pathway diagrams can be drawn with pencil and paper, but it is better to draw them 
using a computer. An electronic pathway diagram in a computer could be automati-
cally linked to online databases that contain information about gene sequences, protein 
structures, chemical reactions and so on. Digitized pathway diagrams could be con-
verted with the press of a button to a format suitable for a PowerPoint presentation or 
a journal publication. A collection of pathways could be indexed and searched quickly 
and easily.
To deal with pathways in software, we created a tool called PathVisio. PathVisio is first 
and foremost a drawing program for pathway diagrams. 
Pathway drawing programs are not new. One of the first programs in this area was called 
GenMAPP. GenMAPP has many good features, such as a user-friendly graphical inter-
face, and the ability to automatically link pathways to large experimental datasets.
But the biggest problem with GenMAPP was that it was written in an old fashioned 
programming language that is not adapted to the age of the Internet. That made it 
hard to implement new ideas and support new experimental methods. For example, 
GenMAPP was heavily focused on transcript measurements, and was not very suitable 
for other types of data. This was a reason to start the development of PathVisio.
Pathway diagrams have been created since the early beginnings of the field of biochemis-
try, often using pencil and paper. But there is no general agreement on the symbols used 
in pathway diagrams. Some diagrams use T-bars (a short perpendicular bar at the end 
of a line) to indicate negative feedback, other diagrams use an arrow with a minus sign 
next to it, yet others use a red color. The lack of standardization discourages researchers 
to make really complex and detailed diagrams, because other researchers will not un-
derstand the symbology without a lot of explanation. Because we are gaining more and 
more detailed knowledge about pathways, there is a need for a good, agreed upon way 
to put that knowledge down in a diagram.
One of the standard notations that is currently being pushed as a standard is called mo-
lecular interaction maps (MIM). PathVisio was the first bioinformatics tool to support 
MIM notation.
A newer system is called Systems Biology Graphical Notation (SBGN). The two are not 
completely separate: SBGN is a newer system that has copied several features of MIM. 
10
A community of biologists is discussing and improving both notation standards. SBGN 
came out after the first version of PathVisio, so it is not yet supported. (The intention is 
that PathVisio will also support SBGN some day).
There is not a single bioinformatics application that is suitable for all research questions, 
or can handle all types of data. A well known bioinformatics application is Cytoscape, 
which, because of its plug-in system, has attracted a large group of bioinformatics de-
velopers. Cytoscape has features that PathVisio does not and vice versa. Therefore it is 
important that the two programs interact. We have enabled interaction by developing 
a plug-in in Cytoscape that can read pathways created in PathVisio. Transferring data 
from PathVisio to Cytoscape is a simple matter of copy and paste. Then Cytoscape can 
be used to improve the pathway, for example using a literature search plug-in, a feature 
that is not available in PathVisio.
wIkIPathways
We have a collection of pathways, which were originally created for GenMAPP, but 
which are also suitable for PathVisio. This collection would be most useful if it was 
always complete and up-to-date with the latest research developments. But keeping it 
up-to-date is a tremendous amount of work. New discoveries are being made all the 
time, and it is nearly impossible for a small group of people to keep up with all the new 
developments. Thus we faced the problem that our pathway collection was doomed to 
lag behind constantly.
In an attempt to solve this problem, we developed WikiPathways. WikiPathways is a 
website, inspired by the successful WikiPedia project, where any researcher can come 
and contribute pathway information. In this way the load of creating pathways and 
checking them against the scientific literature can be shared between a large group of 
people. We call this community curation.
On WikiPathways, each pathway has its own page. On such a page, you see a diagram 
of the pathway, and below that lists of genes, metabolites and literature references, plus 
links to information in other bioinformatics databases. Each pathway can be download-
ed in several formats. But most importantly, just below the diagram there is a big “edit” 
button. After you click that button, you can edit the pathway directly on the website.
We expect that if more people join WikiPathways, the quantity and quality of the path-
way collection will improve. Therefore we tried to make the website easy to use. For 
example, although we like standard graphical notations such as MIM (see above), we do 
not force people to use that out of fear that they would be put off by the extra complex-
ity. Instead, pathways can be drawn in any style.
10
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The pathway history page is another feature that is intended to lower the barrier for 
newcomers. WikiPathways remembers all old versions of each pathway. A newcomer 
may be afraid to edit a pathway out of fear of accidentally messing it up. But because it 
is always possible to go back to an old version, there is no danger of doing permanent 
damage. The absence of this danger removes an important psychological barrier to con-
tributing. On the pathway history page, a visitor can see exactly how a pathway changed 
over time. Old and new versions of a pathway are shown side-by-side, and elements of 
the pathway are colored green if they have been added, red if they have been deleted and 
yellow if they have been modified. 
WikiPathways is an experiment. The number of pathways, and also the number of users, 
is growing slowly but steadily, but it is too early to know if the wiki approach really gives 
good results in the long run.
BrIDgeDB
I have mentioned already several times the possibility to link pathways to online data-
bases. To make that link work, a gene on a pathway must have an identifier. That identi-
fier then points to a record from one of the common bioinformatics databases, such as 
Entrez Gene from the USA or Ensembl from the UK.
Because there are so many different databases, you can choose from many identifiers. A 
record in database X describing gene G may be related to a record in database Y describ-
ing the same gene. Both databases contain almost the same information, but they use 
very different identifiers. To be able to put data from the two together, it is necessary 
to translate identifiers from database X to identifiers from database Y. This problem is 
called the identifier mapping problem, and this problem occurs every time two sets of 
data from different origins are being integrated.
The identifier mapping problem is often very messy. There are dozens of solutions out 
there, but they are very disorganized. For example, some work only for certain species 
– tough luck if you are studying an uncommon organism. You might encounter an 
online tool that does identifier mapping very well, but has a maximum of one thousand 
identifiers.
In an attempt to organize the existing identifier mapping tools, BridgeDb was created. 
BridgeDb is an application programming interface (API) that connects identifier map-
ping services on one side, to bioinformatics tools on the other side. Thus, a bioinfor-
matics tool developer no longer has to choose which identifier mapping service to use 
– by incorporating BridgeDb all of them can be used together. With BridgeDb we took 
existing tools and organized them better so that they could be used more effectively, and 
applied in more situations.
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oPen-source anD oPen access
A very important aspect that returns in all of the projects described in this thesis, 
PathVisio, WikiPathways and BridgeDb, are the principles of open access. Scientists 
never start from scratch: they always use the body of work of thousands of years of sci-
ence before them. So an important academic ideal is the free sharing of information 
between scientists.
In this thesis, there are three types of information that are important to science: pathway 
diagrams, software and publications. All three types of information are important and 
should adhere to the basic principles of free sharing. All manuscripts are (or will be) 
published in open access journals. The source code of software is available under a so 
called open-source license. And access to the pathway data in WikiPathways is governed 
by creative commons licensing.
PuttIng It all together
The goal of this thesis is to develop methods integrate multiple types of experimental data 
and visualize them on pathway diagrams. To meet that goal, we have created PathVisio, a 
tool to edit pathways. We built WikiPathways, a database for community-curated path-
ways. And we have developed BridgeDb, a system for mapping identifiers. Now finally, 
all the pieces of the puzzle can be put together and applied to a scientific study.
In this particular study, we look at the effects of long-term food deprivation in mice. 
Mice were not fed for several days (for a mouse, three days without food is equivalent 
to a whole month for humans). and the state of the cells in the small intestine was 
characterized using two technologies: microarrays on the one hand, which measures the 
amount of transcripts, and 2D Gel electrophoresis on the other hand, which measures 
the amount of proteins. These two datasets have been published before, but now they 
were combined for the first time.
Because we are integrating two diverse datasets, identifier mapping was very important 
to complete this study. For the protein data, Uniprot identifiers were used, for the mi-
croarray data, Agilent identifiers were used. The pathways have a mixture of identifiers 
that is predominantly Entrez Gene. Each type of identifiers had its own problems. For 
example, Agilent identifiers are not available everywhere, and we had to use sequence 
alignment to find the right mapping. The protein identifiers had a couple of mistakes in 
them that could only be fixed manually. However, because of the flexibility of BridgeDb, 
all these problems could be solved.
So what was the result of this analysis? Overall, starvation has an effect on two processes; 
cell turnover and energy metabolism. Both effects can be easily explained. The gut is 
normally a very active site of cell growth. Cells in the inner lining of the intestine con-
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stantly divide, grow and then die off. Naturally, maintaining constant growth costs a lot 
of energy, and this results in the reduction of the cell cycle pathway (which is necessary 
for the growth of new cells), and the apoptosis pathway (which is necessary for cell 
death). The second process that is affected is energy metabolism. Of course, the body 
as a whole tries to save energy as much as possible, but there are important differences 
between organs. The gut for example, stores fat when it is abundant, and during a pe-
riod of starvation, this fat is exported from the gut to the rest of the body. The glycolysis 
pathway is reduced, and lypolysis and gluconeogenesis pathways are activated.
After carefully comparing transcripts and proteins, a couple of interesting things can be 
noticed. Transcripts are the precursors for proteins, so we can normally assume that if the 
amount of transcript increases, the protein also increases. In this study, the average cor-
relation between transcripts and proteins is not as high as you might expect (Spearman 
rank correlation of 0.21). Although transcripts are the precursors for proteins, there are 
several processes in the cell that could affect the correlation between the two.
The picture is very dependent on which gene you look at. Some genes have very good 
correlation between the transcript and the protein, others do not. For elongation fac-
tor 2 (Eef2), the protein expression is reduced, but the transcript clearly increases.  For 
ferritin (heavy and light chain), the transcript is reduced but the protein is increased. 
Another interesting case is that of triose phosphate isomerase 1 (Tpi1), an important 
enzyme in the glycolysis. Analysis of the data shows that a truncated version of the en-
zyme becomes more abundant under starvation conditions, which would be consistent 
with the observation that the glycolysis pathway is reduced in activity. There is not suf-
ficient data to provide an explanation for all these phenomena, but it is clear that these 
proteins are regulated by something other than transcription rate under conditions of 
starvation.
conclusIon
The title of this thesis is “Data Integration with Biological Pathways”. Integration of 
data is currently one of the main problems in bioinformatics. In this thesis, integration 
of information occurs at several levels. Pathway diagrams can be used at one level, to 
integrate various bits of information, such as protein interactions, cellular locations, 
gene identifiers and literature references. At another level, identifier mapping services 
are used to integrate datasets from various sources. And finally, experimental data can 
be integrated with pathway diagrams to create visualizations that make the data easier 
to interpret.
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